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Resumo 
O estudo do genoma humano em muito tem contribuído para o entendimento 
das bases moleculares que estão na origem das doenças genéticas. Neste sentido, a 
criação de bases de dados que reúnem todas as variações genéticas do genoma 
humano, identificadas até ao momento, tem-se revelado um ponto-chave para 
perceber como estas influenciam as características humanas atuais, o risco e 
progressão de doenças, assim como a resposta a diversos tratamentos médicos. A 
deficiência de alfa-1-antitripsina (DAAT) é uma doença monogénica causada por 
mutações no gene SERPINA1 que geralmente culminam numa baixa concentração da 
proteína SERPINA1 no soro. Esta doença afeta um número considerável de 
indivíduos, sendo mais comum em populações de origem Europeia, onde está 
associada com um elevado risco de desenvolver patologias respiratórias, como a 
doença pulmonar obstrutiva crónica (DPOC) ou o enfisema pulmonar. Desde a 
identificação da DAAT em 1963 foram identificados múltiplos alelos com diferentes 
implicações na concentração de proteína no soro, e com subsequentes diferenças ao 
nível das manifestações clínicas da doença. Os alelos mais comuns são os M (M1, 
M2, M3 e M4) que estão relacionados com níveis normais de proteína (0,9 a 2 g/L), e 
os alelos S (Glu264Val) e Z (Glu342Lys) cujos níveis de proteína no soro variam entre 
50-60% e 10-15% do normal, respetivamente. Estes são também os dois variantes 
mais associados com a patologia clínica. Os casos mais severos da doença são 
geralmente verificados em indivíduos homozigóticos para o alelo Z, cuja acentuada 
deficiência da proteína no soro resulta da acumulação intracelular em polímeros nos 
hepatócitos. Por esta razão a DAAT é também associada com um risco de doença 
hepática em consequência dos efeitos tóxicos dos polímeros Z nas células. A 
polimerização do alelo Z foi também proposta como uma das causas possíveis para a 
origem de uma resposta auto-imune nos casos de vasculite. A granulomatose com 
poliangite (GPA) é um síndrome multissistémico prevalente entre pacientes com DAAT 
e caracterizada por inflamações granulomatosas nos pequenos vasos. Outros 
mecanismos que têm sido apontados na origem da GPA incluem o desequilíbrio 
proteolítico entre a proteinase 3 (PR3) e a sua principal inibidora no soro a SERPINA1, 
bem como uma possível hereditariedade de genes auto-imunes transmitidos 
conjuntamente com genótipos de DAAT devido à sua proximidade no cromossoma 
14q32.1. O gene SERPINA2 localizado 12kb a jusante do gene SERPINA1 possui 
uma sequência de DNA muito similar a este e embora tenha sido durante muito tempo 
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considerado um pseudogene, o gene SERPINA2 possui uma forma ativa de função 
desconhecida que é expressa em diferentes tecidos incluindo nos leucócitos.  
 O principal objetivo deste trabalho foi identificar e caracterizar alelos raros de 
DAAT na população Portuguesa. No sentido de obter mais informação sobre as bases 
moleculares e a variabilidade intra-haplotípica de cada variante combinou-se a 
sequenciação de DNA de uma região de ~8kb do gene SERPINA1 com a 
genotipagem de dois microssatélites flanqueantes CAn (~7,5kb a jusante) e GTn 
(~207kb a montante). De entre os 51 casos de DAAT sequenciados foram 
identificadas 13 mutações patogénicas num total de 14 alelos raros: MMalton (Phe52del; 
n=18), MPalermo (Phe52del; n=9), I (Arg39Cys; n=7), Q0Ourém (Leu353framStop376; n=4), 
PLowell (Asp256Val; n=3), MHerleen (Pro369Leu; n=2), MWurzburg (Glu342Lys; n=1), Q0Lisbon 
(Thr68Ile; n=1), T (Glu264Val; n=1), Q0Gaia (Leu263Pro; n=1), PGaia (Glu162Gly; n=1), 
Q0Oliveira do Douro (Arg281framStop297; n=1), Q0Vila Real (Met374framStop392; n=1) e 
Q0Faro (IVSIC+3Tins; n=1). Os últimos cinco alelos são novos e descritos pela primeira 
vez no presente trabalho. Os alelos Q0Gaia e PGaia resultam ambos de substituições de 
aminoácidos com repercussões na estrutura da proteína. Os variantes Q0Oliveira do Douro e 
Q0Vila Real resultam de pequenas deleções nucleotídicas que estão na origem da 
alteração da matriz de leitura e da inserção de codões de terminação prematura. O 
alelo Q0Faro afeta o normal processamento do mRNA por alteração de um local de 
splice.  
A análise da variação haplotípica permitiu avaliar os alelos anteriormente 
descritos em populações de ancestralidade Europeia e elucidar a origem dos alelos 
raros MMalton e MPalermo em bases moleculares distintas M2 e M1, respetivamente. A 
avaliação do espetro mutacional aponta para o facto de uma percentagem das 
mutações do gene de SERPINA1 ocorrem em regiões hipermutáveis, enquanto os 
motivos repetitivos tendem a acumular mutações do tipo inserções e deleções (indels), 
os dinucleótidos CpG apresentam um número elevado de substituições nucleotídicas 
preferencialmente de CGTG e de CGCA. Por outro lado, a análise da distribuição 
das mutações patogénicas e não patogénicas na região codificante do gene de 
SERPINA1 mostra que as mutações patogénicas se tendem a concentrar em 
importantes domínios funcionais da molécula, por oposição às mutações não 
patogénicas que se encontram dispersas uniformemente por toda a sequência de 
SERPINA1.  
Numa segunda parte do trabalho procuramos avaliar o gene SERPINA2 como 
um potencial candidato para a associação observada entre a SERPINA1 e a GPA. 
Apesar de preliminares, os nossos resultados apontam para uma maior 
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homogeneidade haplotípica nos controlos face aos casos de GPA, o que levanta a 
hipótese do haplótipo mais frequentemente associado com alelo Z (SERPINA2/V3) 
apresentar um fator protetor. No âmbito deste trabalho, foram ainda realizados alguns 
ensaios experimentais de expressão de SERPINA2 em células humanas, HEK293, e 
em células de Drosophila Schneider S2. Embora a expressão da SERPINA2 tenha 
sido obtida em ambos os sistemas celulares, nas células Schneider S2 foram 
conseguidos níveis de proteína mais elevados em grande parte devido à acumulação 
intracelular da SERPNA2 nas células HEK293. 
 
 
Palavras-chave: Deficiência de alfa-1-antitripsina, SERPINA1, alelos raros, 
haplótipos, mutações patogénicas, Granulomatose com poliangite, SERPINA2.  
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Abstract   
The study of the human genome has greatly contributed to the understanding of 
the molecular basis of genetic diseases. In this sense, the creation of databases that 
gather all the genetic variations in the human genome identified so far, has proved a 
key point to understand how these influence current human traits, disease risk and 
progression, as well as the response to various clinical treatments. The alpha-1-
antitrypsin deficiency (AATD) is a monogenic disease caused by mutations in the 
SERPINA1 gene, which generally culminate in low serum levels of the SERPINA1 
protein. The disease affects a considerable number of individuals, being more frequent 
in populations of European descended, where it is associated with a high risk of 
developing respiratory diseases, such as chronic obstructive pulmonary disease 
(COPD) or lung emphysema. Since the description of AATD in 1963 multiple alleles 
were identified and these were found to correlate with different serum levels and 
clinical manifestations of the disease. The most common alleles are M (M1, M2, M3 
and M4) which are associated with normal protein levels (0.9 to 2 g/L) and the S 
(Glu264Val) and Z (Glu342Lys) alleles whose protein levels range between 50-60% 
and 10-15% of the normal, respectively. The last two are also the most commonly 
associated variants with respiratory complaints. The most severe cases of the disease 
are usually observed in Z homozygous in which the serum deficiency is determined by 
the intracellular accumulation of Z polymers in the hepatocytes. For this reason AATD 
has also been associated with an increased risk of liver disease as a result of toxic 
effects of the Z polymers within the cells. The polymerization of the Z allele has been 
proposed to underlie an autoimmune response in the case of vasculitis. 
Granulomatosis with poliangite (GPA) is a multisystemic syndrome affecting patients 
with AATD, which is characterized by a small vessels granulomatous inflammation. 
Other mechanisms that have been suggested to play a role in GPA include the 
proteolytic imbalance between proteinase 3 (PR3) and its major inhibitor in serum, 
SERPINA1, and the co-inheritance of autoimmune genes and AATD genotypes mainly 
due to its close proximity in chromosome 14q32.1. SERPINA2 is located 12kb 
downstream of the SERPINA1 and share with this a high DNA sequence similarity. 
Although SERPINA2 has been regarded as a pseudogene for a long time it has an 
active isoform of unknown function that is expressed in different tissues including in 
leukocytes. 
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The main goal of this work was to characterize rare alleles of AATD in the 
Portuguese population. In order to obtain additional information about the molecular 
basis and the intrahaplotipic variability of each variant, we combined the DNA 
sequencing of 8 kb region of the SERPINA1 with the genotyping of two flanking 
microsatellite CAn (~7.5 kb downstream) and GTn (~207 kb upstream). Among the 51 
AATD cases analysed we have identified 13 pathogenic mutations in a total of 14 rare 
alleles: MMalton (Phe52del n = 18) MPalermo (Phe52del n = 9), I (Arg39Cys, n = 7) Q0Ourém 
(Leu353framStop376 n = 4) PLowell (Asp256Val, n = 3) MHerleen (Pro369Leu, n = 2) 
MWurzburg (Glu342Lys, n = 1) Q0Lisbon (Thr68Ile n = 1), T (Glu264Val, n = 1), Q0Gaia 
(Leu263Pro n = 1) PGaia (Glu162Gly, n = 1) Q0Oliveira doDouro (Arg281framStop297 n = 1) 
Q0Vila Real (Met374framStop392, n = 1) and Q0Faro (IVSIC+3Tins, n = 1). The last five 
alleles are novel and are described for the first time in this work. The Q0Gaia and PGaia 
alleles both result from amino acid substitutions affecting the protein structure. The 
Q0Oliveira do Douro and Q0Vila Real variants result from small deletions causing alterations of 
the reading frame and the insertion of premature termination codons. The Q0Faro allele 
affects the normal mRNA processing by disrupting a splice site. 
The haplotype variability analysis allowed the evaluation of the alleles 
previously described in other populations with European ancestry and to elucidate the 
independent origin of MMalton and MPalemo alleles in the M2 and M1 molecular basis, 
respectively.  
The assessment of the mutational spectrum indicates that a proportion of the 
SERPINA1 mutations occur in hypermutable regions and while short repetitive motifs 
tend to accumulate insertions and deletions (indels), the CpG dinucleotides display a 
large number mutations preferably from CGTG and CGCA. Furthermore, the 
analysis of the distribution of pathogenic and non-pathogenic mutations across 
SERPINA1 coding region shows that pathogenic mutations tend to cluster in crucial 
functional domains of the molecule, in opposition to the non-pathogenic mutations, 
which are more uniformly spread throughout the SERPINA1 sequence.  
In the second part of the work, we evaluate SERPINA2 as a potential candidate 
gene for the reported association between SERPINA1 and GPA. For this purpose, we 
conducted a sequencing study in control samples (ZZ individuals without disease), and 
GPA cases. Our preliminary results point to a higher haplotype homogeneity in controls 
than in GPA cases. We hypothesized that the haplotype more often associated to the Z 
allele (SERPINA2 / V3) may provide a protective factor to GPA. In this work, we have 
also performed several experimental assays of SERPINA2 expression in human 
HEK293 cells and in Drosophila Schneider S2 cells. Despite SERPINA2 expression 
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was achieved in both cellular systems, in Schneider S2 cells higher levels of protein 
were collected due to intracellular accumulation of SERPINA2 in HEK293 cells. 
 
 
Key-words: Alpa-1-antitrypsin deficiency, rare alleles, SERPINA1, haplotypes, 
pathogenic mutations, Granulomatosis with polyangiitis, SERPINA2. 
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The understanding of the molecular basis of human diseases has been a major 
challenge for the scientific community for several decades, as well as the finding of 
their causes, susceptibility factors and treatment to improve the life quality of the 
patients. 
In this sense, the progress achieved in the field of human genetics and the efforts 
made in the last years to generate a reference human genome sequence (Human 
Genome Project) and more recently, a database with thousands of sequenced 
individuals from different geographic regions (1000 Genomes Project) are 
remarkable1,2. Altogether,  these projects allowed to create a detailed catalogue of the 
human genetic variation, which to date represents a fundamental tool to address how 
genetics influence current human traits, disease risk and progression and the response 
to different medical treatments1.  
The human genome comprises the following categories of sequence variants: 
single nucleotide polymorphisms (SNPs), insertions and deletions (INDELs) which may 
range from 1bp to 10kb in length and larger structural variants (also known as copy 
number variation), which extend from 10 kb to several megabases2. Another class of 
genetic variants includes minisatellites and microsatellites2, which are tandem repeated 
DNA sequences of 6 bp to 100bp units and 1 to 5 bp units, respectively3. The most 
common category of variants involves a mutation in a single base in the DNA (SNPs), 
whereas other categories include the loss (deletion) or the gain (duplication or 
insertion) of one or multiple nucleotide(s). Sequence variants may have different 
repercussions according to their localization in a gene. If a mutation occurs in the 
coding region of a gene they can (1) have no effect or (2) result in an altered protein 
product unable to perform its regular function or (3) cause the protein premature 
termination. Otherwise if a variant occurs in a regulatory region, it may compromise the 
regular expression of a gene or even inactivate the entire gene. Importantly, mutations 
might also be classified as a “loss of function” if they drastically affect the normal 
activity of a gene or as a “gain of function” mutation,  if the mutated gene acquires a 
novel property or function4.  
 However, in most cases the understanding of the impact of the different 
categories of variants in human health and disease is far from being completed.  
Genetic diseases affect thousands of individuals around the world and in most 
cases these are expected to result from a mutation, which occurred in a germ cell and 
was then transmitted to the following generations. If the mutation has a strong effect 
and occurs in a single gene the disease will be monogenic (or Mendelian disease) and 
the inheritance pattern, might be autosomal or X-linked dominant, autosomal or X-
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linked recessive or Y-linked or mitochondrial5. Most of these diseases are detected at 
low frequencies in the random population (rare diseases less 1%). Once the underlying 
genetic alteration has been identified, it is easier to understand the molecular 
pathogenesis of the disease and to design a genetic test for the diagnosis of the 
disease. Classical examples of monogenic diseases include alpha-1-antitrypsin 
deficiency (AATD), cystic fibrosis, phenylketonuria and Huntington’s disease, which are 
all correlated with the occurrence of pathogenic mutations in single genes6,7,8,9.  
 On the other hand, if several mutations with smaller effects occur in multiple 
genes, the disease is defined as complex or multifactorial and in general, these 
diseases may affect a larger percentage of the population. In this case, interactions 
among genes and between genes and the environment are likely to have an important 
role in the disease phenotype and in the molecular mechanism of the disease, thus 
making the design of screening tools much more difficult10. Here chronic obstructive 
pulmonary disease (COPD), antineutrophil cytoplasmic antibodies (ANCA) associated 
vasculitis, diabetes and Crohn’s disease are some examples of complex diseases 
associated with genetic variants distributed over multiple loci11-14. Worth of note, in 
most cases of complex diseases a significant proportion of their heritability still remains 
unexplained5.  
1.1 The SERPIN Superfamily  
 
SERPINs (serine proteinase inhibitors) are a superfamily of functional diverse 
protease inhibitors, sharing a conserved tertiary structure, which is determined by 
about 350 to 400 amino acids and has a molecular weight of 40-50 KDa15,16.  Hundreds 
of SERPINs were already found in viruses, prokaryotes, plants, and animals where 
they are involved in many diverse physiological processes17. For example, in 
vertebrates SERPINs have key roles as protease inhibitors in blood coagulation, 
fibrinolysis, inflammation, angiogenesis, apoptosis and in complement activation. 
However, some SERPINs have developed other non-inhibitory functions, and act as 
molecular chaperones, hormone carriers or as storage proteins15.   
The archetypical SERPIN structure has three β-sheets (A,B,C), nine α-helices (A-
I), and  a flexible stretch of approximately seventeen residues between β sheet A and 
C named the reactive center loop (RCL) (Figure 1A), which is normally exposed to the 
solvent acting as a pseudo-substrate for proteases18. SERPINs ability to inhibit a 
specific protease is determined by the amino acid composition of the RCL, in particular 
those located at residues P1-P1’. Once a protease binds to the RCL, it establishes a 
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covalent ester linkage between the protease residue Ser-195 and the backbone 
carbonyl of the P1 residue leading to the cleavage of the P1-P1’ peptide bond. Such 
event initiates a major conformational rearrangement in SERPINs, and the molecule 
undergoes a complete transition from a “stressed” to a “relaxed” state (S to R 
transition). Briefly, immediately after the cleavage, the RCL is rapidly inserted into the 
β-sheet A (shutter region), caring the protease to the opposite site of the SERPIN 
molecule, distorting the catalytic domain of the protease and consequently the entire 
molecule (Figure 1B). This distortion avoids the breakdown of the acyl-enzyme 
intermediate, resulting in an irreversible SERPIN protease complex16, 19.  
 
1.2 The Alpha-1-antitrypsin (SERPINA1) 
 
One of the most studied SERPINs is alpha-1-antitrypsin (SERPINA1 or AAT), a 
52-kDa plasma glycoprotein with 394 amino acids synthesized at high levels by 
hepatocytes, and at lower concentrations by intestinal epithelial cells, neutrophils, lung 
epithelial cells and macrophages20. The protein is encoded by the SERPINA1 gene 
located at chromosome 14q32.1, which covers approximately 12.2 kb, and has four 
coding exons, three untranslated exons and six introns (Figure 2). The untranslated 
region of SERPINA1 comprises exons IA to IC and controls SERPINA1 expression 
through three alternative transcription initiation sites (Figure 2). While transcription may 
start in exons IA or IB in macrophages (middle and beginning of the exon, 
respectively), the transcription in hepatocytes is initiated only at exon IC (middle of the 
exon)20.  
SERPINA1 is an important acute phase protein and the major serine protease 
inhibitor of human plasma, where it shows strong affinity towards neutrophil elastase 
(ELANE2) and proteinase 3 (PR3). However, recent studies have shown that 
SERPINA1 is also an irreversible inhibitor of kallikreins 7 and 14 and it has the ability to 
inhibit intracellular and cell-surface proteases such as matriptase and caspase-321. 
This inhibitory activity is mainly conferred by methionine 358 and serine 359 residues 
which correspond to RCL P1-P1’, respectively. The principal site of SERPINA1 activity 
is in lung, where the protein protects the fragile connective tissue of the lower 
respiratory tract from the uncontrolled proteolysis triggered by neutrophils during 
inflammation6. Importantly, in recent years SERPINA1 has emerged as a complex and 
multifunctional protein combining inhibitory properties with immunomodulatory and anti-
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inflammatory activities against neutrophils, lymphocytes, macrophages, monocytes, 
mast cells and epithelial cells22. 
 
Mutations in the SERPINA1 gene are the main cause for alpha-1-antitrypsin 
deficiency (AATD), an autosomal-codominant disorder, characterized by reduced 
protein serum levels and affecting 1 in 2000 to 1 in 7000 individuals of European 
descent24. The disease was first described by Laurell and Eriksson in 1963, when they 
noticed the absence of the SERPINA1 band by plasma protein gel electrophoresis in 
patients with COPD and lung emphysema25. Indeed, AATD patients have a significant 
higher risk of developing pulmonary disease, like early-onset emphysema and chronic 
obstructive pulmonary disease (COPD), which is correlated with the uncontrolled 
activity of neutrophil elastase in the lungs. Another major clinical manifestation of AATD 
is liver cirrhosis as a result of the cytotoxic effect of protein accumulation in the 
hepatocytes26. Presently, there are more than 125 variants of SERPINA1 identified and 
a considerable large number of those variants may be associated with abnormal 
protein plasma levels. Accordingly, SERPINA1 alleles are classified as: 1) “deficient” if 
they are associated with a significant reduction in plasma levels, either because the 
synthesized protein is misfolded and retained within hepatocytes or because it has 
poor stability,  leading always to reduced secretion; 2) “null” alleles (Q0), if there are no 
Figure 1: SERPINA1 structure. SERPINA1 comprising three β-sheets and nine α-helices. A –The shutter region (β-
sheet A) is highlighted in red and the RCL is shown in magenta. B – Stable protease inhibitor complex.   (Adapted from 
Khan et al. 16  Whisstock et al. 
23
) 
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protein traces in the plasma27. While, deficiency variants can be easily identified by 
isoelectric focusing (IEF) techniques, where different letters are assigned to different 
gene products according to the migration velocity in the protein electrophoresis gel (M 
to medium; S to slow; F to fast and Z very slow); null variants are characterized by the 
absence of a visible band in the IEF gels28.  
 
 
 
In European populations only the alleles M1, M2, M3, M4, S and Z reach 
polymorphic frequencies (>1%). The M alleles are considered the normal ones with 
100% levels of the plasma protein (0.9 to 2 g/L) and the S and Z alleles, the common 
deficiency variants, are associated with 50-60% and 10-15% of normal plasma 
concentrations, respectively. The analysis of the molecular basis of the M, S and Z 
alleles allowed the reconstruction of the phylogenetic relationships between SERPINA1 
common variants (Figure 3). The M1 can be subdivided in two subtypes, the M1Ala213 
(ancestral allele) and the M1Val213. The M3 differs from the M1Val213 by an amino 
acid replacement at codon 376 (Glu376Asp) and the M2 has another substitution at 
codon 101 (Arg101His). The M4 shares with M2 the Arg101His substitution but lacks 
the Glu376Asp found in M3 and M2 variants (Figure 3)29. The S allele results from a 
Glu264Val mutation, in exon III, in a M1Val213 background. The Glu264Val causes the 
disruption of a salt bridge (Glu264-Lys387), highly conserved among SERPINs and 
linking the C terminus of the G α-helix to a β-strand in the hydrophobic core of the 
Figure 2:  Schematic representation of SERPINA1. The gene is located in SERPIN 14q32.1 
cluster and it is organized in 3 untranslated exons (IA-IC), 4 coding exons (II-V) and 6 introns.  
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molecule18. This mutation is known to alter the stability of the molecule and to increase 
the susceptibility of the protein to polymerize, however it is only associated with 
disease when it is heterozygous with the Z allele30.  Conversely, the Z allele arose by a 
Glu342Lys substitution in exon V, within a M1Ala213 allele. The Glu342Lys causes the 
disruption of another crucial salt bridge (Glu342-Lys290), which in turn affects the 
stability of A β-sheet. Importantly the Z mutation has more serious repercussions in 
protein folding than the S mutation because it leads to the spontaneous polymerization 
and accumulation of polymerised fibrils in the endoplasmic reticulum of hepatocytes, 
with subsequent cell damage18, 31.  
 
 
The polymorphism of SERPINA1 has been widely studied in several populations 
due to its importance in human health32. The M alleles (M1, M2 and M3) are present in 
ethnical diverse populations, such as Europeans, Africans and Amerindians, with some 
differences in their frequencies. The M4 allele has also been reported in multiple 
samples from diverse geographic regions, but this variant is less studied than the other 
M subtypes because it is difficult to discriminate using only isoelectric focusing 
techniques. In contrary to M alleles, S and Z variants are only present in populations of 
European descent, or in cases of miscegenation with Europeans. The S allele is 
broadly distributed among the European continent, but its values tend to increase from 
northeast to southwest reaching the higher frequencies in the Iberian Peninsula, with 
an increase of more than 70 cases per 1000 individuals. This distribution suggests that 
the S mutation may have arisen in the north of the Iberian Peninsula in prehistoric 
times and then spread eastwards by population movements (Figure 4A). This 
hypothesis is supported by the 8500-16500 years estimate of the S allele obtained for 
Figure 3:  Phylogeny of SERPINA1 common alleles. (Adapted from Seixas et al.
32
). 
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the Portuguese population, which are close to the end of the last glaciations (18000 
years ago) and the European population expansion from the glacial refuge in the 
Iberian Peninsula32, 33. 
  The Z mutation has a different distribution among European populations, the 
frequency is higher in the north-east, more precisely in Scandinavia and the Baltic 
region where it can reach average values of about 2-4 %34 while in south populations it 
varies between 0.19 and 0.30% (Figure 4B). In summary, it has been suggested that 
the Z mutation occurred in the southern Scandinavia and Baltic regions about 2000-
5000 years ago and spread later throughout the continent during Neolithic times 21, 33, 35, 
36, 37.   
 
 
 
Figure 4 : Distribution of S and Z alleles in the European continent. A – Frequency of S alleles 
per 1000 inhabitants. B- Frequency of Z alleles per 1000 inhabitants (Adapted from Blanco et al.
37
)  
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1.3 SERPINA1 variation and human disease 
 
Lung emphysema is the principal clinical manifestation of AATD, which is 
associated with SERPINA1 concentrations below a protective threshold of 11 µM 
(0.50g/L)6,38. Although different SERPINA1 genotypes may lead to such reduced serum 
levels (Table 1) the most common genotype is the ZZ, which represents approximately 
95% of the cases of severe AATD39. The SZ genotype is also associated with a lower 
risk of lung disease since protein levels are close to the 11 µM6.  
 
Table 1: SERPINA1 serum levels in different genotypes and corresponding risk of developing emphysema  or liver 
disease. (adapted from Bals et al. 
6
) 
Genotype 
SERPINA1 serum 
levels (mol/L) 
Risk of lung 
disease 
Risk of liver disease 
MM 20-48 No risk No risk 
MZ 17-33 Minimal risk Minimal risk 
SS 15-33 Low risk No risk 
SZ 8-16 Low risk Minimal risk 
ZZ 2.5-7 High risk High risk 
Null 0 High risk Dependent of the mutation 
 
Among ZZ individuals emphysema is the most common cause of death (58-
72%) and tends to appear in early ages, around 40 to 50 years in smokers or around 
60 to 70 years in non-smokers40. Pathogenesis of the lung disease in ZZ individuals 
has been mostly associated with the unopposed activity of neutrophil elastase and the 
elastolytic damage of the lung extracellular matrix39.  However, recent findings suggest 
that the polymerization of Z variant may occur in other tissues beyond hepatocytes, 
including in peripheral tissues such, as the lung. There, SERPINA1 polymers may 
delay or arrest the neutrophils within the lung interstitium promoting their cellular 
adhesion and, degranulation with the subsequent release of proteolytic enzymes. 
These events cause additional damage in the extracellular matrix and contribute to the 
spread of the focus of inflammation throughout the lung lobules. Such physiological 
response activates the production of several inflammatory mediators, which amplifies 
the recruitment of neutrophils to the damaged tissue and further increases the 
proteolysis of the extracellular matrix. Furthermore, the lack of a functional SERPINA1 
also contributes to an uncontrolled activation of apoptotic cascades hence causing 
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alveolar cell death and the characteristic panlobular distribution of emphysema (Figure 
5)41.  
Besides its role in lung emphysema the Z allele is also an important risk factor 
for chronic obstructive pulmonary disease (COPD), which is  defined as the presence 
of airflow obstruction that is not fully reversible (American Thoracic Society,2003)42.  In 
ZZ individuals the lung emphysema may be preceded by a COPD phase, however in 
COPD there is growing evidence for a MZ genotype representing a significant risk 
factor, too. In general MZ individuals show more pronounced breathlessness and 
wheezing when compared with MM genotype, and the MZ subjects have a 2.2% higher 
probability of being hospitalized when the disease manifests than MM individuals. Like 
in emphysema, the smoking history is also an important environmental risk factor for 
COPD and the disease frequently appears at early ages in MZ smokers than non-
smokers42.     
  Liver disease is another common clinical manifestation of AATD observed 
among ZZ individuals. Here, the key factor for disease development is the formation of 
SERPINA1 polymers and the cytotoxic effect of SERPINA1 granules in the 
endoplasmic reticulum (ER) of hepatocytes. In spite of being correctly transcribed and 
assembled on the ribosome, the Z protein once translocated to the ER lumen folds 
slowly and inefficiently leading to an abnormal conformation in which multiple 
molecules aggregate to form polymers. Under normal circumstances cellular 
mechanisms are activated to direct misfolded proteins to a series of proteolytic 
intracellular pathways of degradation. However, in cell lines derived from ZZ individuals 
affected by severe liver disease, a lag in ER degradation of SERPINA1 is observed43. 
Several environmental and genetic factors are currently thought to influence the 
balance between the accumulation of cytotoxic SERPINA1 aggregates and the activity 
of different intracellular mechanisms of protein degradation. The increased synthesis 
during systemic inflammation, the increment of body temperature32, and viral infections 
like hepatitis B and C are known to promote the increase of Z load and its  
polymerization, and to cause ER stress in hepatocytes6. In addition, alcohol and large 
fat consumption are other factors causing liver injury also contributing to disease 
progression6. On the other hand, recent studies have also identified several 
polymorphisms at different genes enrolled in the pathways of Z allele degradation 
predisposing to liver disease associated with AATD (Figure 5)44.   
The liver disease in ZZ homozygous can arise in childhood and/or adulthood. In 
children, the most common pathology is neonatal hepatitis, characterized by the 
occurrence of conjugated hyperbilirubinemia, hepatomegaly and elevated 
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Figure 5: Pathophysiology of SERPINA1 and its 
deficiency (AATD). SERPINA1 synthesis, secretion 
and circulation into the lungs of healthy individuals 
(top). How the liver and lungs are adversely affected in 
the classical form of disease (below) (Figure from 
Ghouse et al.
44
) 
transaminases and it can be simply explained by the immaturity of the hepatic 
metabolism. In adults, the disease manifests as chronic hepatitis, cirrhosis, portal 
hypertension or hepatocellular carcinoma and it is partially correlated with a decline of 
liver function with aging32.  
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Only 17% of ZZ subjects have hepatic dysfunction earlier in life and among 
these only a third (7% of all ZZ individuals) have severe disease, culminating in fatal 
cirrhosis at young ages32. Similarly, in adults only a small fraction of ZZ individuals 
develops liver disease (15% to 20%), and in most cases these are men over 50 years 
with cirrhosis. In rare instances SZ heterozygotes may also show signs of liver disease 
associated with AATD. Nevertheless, some rare alleles have been shown to cause 
intrahepatic SERPINA1 accumulation and in the particular case of MMalton allele, liver 
disease was inclusively reported in cases of heterozygosity with M non-deficiency 
alleles6.   
Besides pulmonary and liver diseases other disorders have been consistently 
associated with AATD to a lesser extent, this is the case of panniculitis and vasculitis 
such as Wegener’s granulomatosis.  
Panniculitis is a skin disorder characterized by inflammation and necrotizing 
lesions in subcutaneous tissues, which preferably manifests in trunk and proximal 
extremities. Many conditions may cause panniculitis including AATD which currently 
represents the most important genetic risk factor for the disease. In general, patients 
with severe AATD caused by  ZZ homozygosity seem to be the most affected group 
but cases of panniculitis complicated by AATD have been observed in SZ, SS, MZ and 
even in MS genotypes45. In the AATD panniculitis associated syndrome skin lesions 
due to neutrophilic inflammation in subcutaneous nodules and tissue inflammation can 
persist for months progressing from an acute to chronic stage. Several mechanisms 
were proposed to drive AATD-associated panniculitis including the accumulation of 
neutrophils and Z polymers in affected tissues and the subsequent implications in the 
inflammatory processes. Here, Z polymers are thought to contribute directly to 
neutrophil recruitment and chronic inflammation46.  
 The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a 
complex systemic disorder of small vessels, which is subdivided in three major clinical 
syndromes, namely granulomatosis with polyangiitis (GPA), formerly known as 
Wegener’s granulomatosis, microscopic polyangiitis (MPA), and Churg-Staruss 
syndrome47. GPA is the most prevalent ANCA syndrome among AATD patients and it 
is defined as a multisystemic disorder characterised by necrotising granulomatous 
inflammation and pauci-immune small-vessel vasculitis. In the initial phase of disease 
affected patients have upper airways symptoms, such as nasal discharge, sinusitis or 
epistaxis caused by the granulomatous inflammation. Other organs may also be 
implicated in the initial stages of the disease such as the trachea, bronchi and lung 
parenchyma. Later on, the disease progresses to a vasculitis phenotype stage with 
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arthralgias, cutaneous vasculitis, mononeuritis or polyneuritis. In addition, more than 
70% of the patients also have renal complications as a result of necrotising 
glomerulonephritis48. The most common molecular signature of GPA patients is the 
presence of auto-antibodies against proteinase 3 (PR3), an elastase-like serine 
protease normally synthesized by neutrophils and located in granules and on their 
surface47,49. Although the relation between GPA and AATD still remains poorly 
understood, three mechanisms for the pathogenesis of the disease have been 
proposed. The first suggests the proteolytic imbalance between PR3 and SERPINA1, 
as an adverse process once the vasculitis syndrome is initiated, since SERPINA1 is 
the major inhibitor of PR3 in the extracellular fluids. Here, the low levels of SERPINA1 
in the plasma could play a role in the development of autoimmunity through the 
circulating levels of unopposed PR3, acting as antigen. The second mechanism 
proposes a coinheritance of autoimmune genetic variants along with the SERPINA1 
deficiency genotypes due to its close proximity on chromosome 14q32.1. The last 
hypothesis assumes that the Z polymerization in the liver may trigger autoimmune 
vasculitis responses42. The Z polymerization together with low plasma levels may result 
in an ineffective inhibition of normally controlled proteolytic enzymes or lead to the 
formation of circulating immune complexes that cause diffuse systemic vasculitis50, 51.      
 In a recent genome-wide association study for ANCA associated vasculitis 
performed in cases and controls from Northern Europe, SERPINA1 was confirmed as 
one of the most prominent genes associated with GPA and PR3 ANCA vasculitis. 
Indeed, the SNP with the strongest P-value (rs7151526) was located upstream of the 
SERPINA1 gene and in linkage disequilibrium with the Z allele. The absence of a 
significant association with the disease independently of Z allele indicates that the 
causal variant is either the Z allele itself or another variant strongly associated with the 
Z allele (Figure 6)52.  
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Figure 6: The SERPINA1 locus shows differential associations with anti-PR3 positive patients. A – Association of 
SNPs at the SERPIN locus with all ANCA associated vasculitis, B – with anti-PR3 positive cases only. C – The genomic 
architecture of the SERPIN locus indicates cumulative genetic distance from the most associated SNP and haplotype 
block structure. The grey lines indicate the genomic location of the most associated SNP together with the defining S 
and Z alleles. (Adapted from Lyons et al.
52
)  
 
1.4 SERPINA2 
The nearest SERPINA1 neighbours are positioned 52 kb upstream 
(SERPINA11) and 12 kb downstream (SERPINA2). The latter has a high DNA 
sequence similarity to SERPINA1 but it has been regarded as a pseudogene due to a 
2kb deletion encompassing exon IV and part of exon V53. However, an active isoform 
of SERPINA2 segregates within human populations and it has been shown to be 
expressed in vitro and in vivo in leukocytes54. In addition, the active SERPINA2 is 
conserved in primates, where it originated by gene duplication from SERPINA1 and 
diverged into a SERPIN with a distinct inhibitory activity. In SERPINA2, the P1 residue 
of the RCL (P1-P1’) is a tryptophan instead of a methionine54.  
The frequency of the active SERPINA2 largely differs across human 
populations and it is predicted to vary between Europeans and Africans. While in 
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Europeans the active isoform is more frequent in African and Amerindians the disrupt 
SERPINA2 form is the most prevalent (Figure 7)53. Furthermore, several genetic 
variants were identified in the full SERPINA2 including premature stop codons 
(Leu108framStop and Leu277framStop) and four amino acid replacement variants 
(Ile280Thr, Leu308Pro, Glu320Lys and Pro387Leu). Previously the Leu308Pro and the 
Pro387Leu were predicted to alter protein structure based on computational tools53. 
However, no clear differences were detected between three SERPINA2 variants (V1: 
Pro308-Lys320; V2: Leu308-Glu320; and V3: Pro308-Glu320) used for the transfection 
of mammalian cell lines54. 
 
 
Figure 7: Distribution of SERPINA2 non-functional alleles in 52 human populations. (Human Genome Diversity 
Panel samples) 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
2. Aims 
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The current work will focus on the characterization of SERPINA1 rare variants 
underlying cases of AATD in Portugal and on the analysis of the functional 
repercussions, haplotype background and geographical distribution of different 
SERPINA1 variants. For this purpose we took advantage from our sample collection 
comprising a few dozens of AATD cases caused by rare SERPINA1 alleles and from 
publically available databases of genome variation. We combined the DNA sequencing 
of SERPINA1 with the genotyping of two flanking microsatellites to assess the 
molecular basis of each rare allele as well as their intrahaplotipic variability. In addition, 
we compile the published information from SERPINA1 variation and from 
1000Genomes and NHLBI GO Exome Sequencing Project to evaluate the distribution 
of rare alleles in human populations and correlate the level of each mutation with 
pathogenicity and SERPINA1 patterns of residue conservation.      
In a second part of the work, we will explore the hypothesis of SERPINA2 as a 
potential candidate gene for the observed genetic association with GPA. Theoretically, 
a non-functional SERPINA2 variant could contribute to a higher susceptibility to GPA 
by increasing the chance of bacterial infections (unopposed bacterial proteases) or by 
an uncontrolled activity of endogenous proteases. To achieve our goal, we started by 
increasing the density of sequence variants within SERPINA2 in both GPA cases and 
controls (ZZ individuals without the disease) on one hand, and on the other hand by 
further investigating the inhibitory properties of SERPINA2. To this end, we expressed 
SERPINA2 in novel host cell models (HEK293 and Schneider S2 cells). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.Material and Methods  
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3.1 Severe AATD by rare SERPINA1 variants  
     3.1.1 Samples 
Our sample included 51 unrelated individuals and a few relatives (father, 
mother and/or siblings) requested to perform SERPINA1 genotyping after a first 
screening of AATD by quantitative analysis of serum levels (radial immunodiffusion or 
nephelometry). The SERPINA1 genotyping was done previously as a part of the AATD 
diagnostic service at IPATIMUP, which combines the serum protein analysis by 
isoelectric focusing55 and the analysis of common mutations (Arg101His, Ala213Val, 
Glu264Val and Glu342Lys) by multiplex PCR56.  All cases were found to carry rare 
SERPINA1 variants. Blood samples were collected using EDTA as anticoagulant and 
then frozen separately as serum and cellular fraction (leukocytes and erythrocytes).    
 
3.1.2 DNA extraction  
  DNA was isolated from the frozen blood cellular fraction. DNA was extracted 
using the Generation Capture Column Kit (Qiagen) according manufacturer’s protocol.  
3.1.3 PCR and sequencing  
 The DNA amplification was done in three different PCR reactions as illustrated 
in Figure 8. Briefly, SERPINA1 gene was subdivided into three different fragments of 
about 2.6 kb (F1) and 2.7 kb (F2 and F3). The first fragment comprised the promoter 
region spanning from exons IA to IC, the second fragment included exons II and III, 
and finally the third fragment included exons IV and V. Fragment 2 and 3 had a small 
overlap in intron III.  
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Amplification of SERPINA1 fragments from genomic DNA was done by long 
PCR using the cycling conditions described in Table A1 (Appendix) and the following 
reagents: 0.5 µM of forward and reverse primers, 200 µM of dATP, 200 µM of dTTP, 
200 µM of dGTP, 200 µM of dCTP, 4% of DMSO, 1.75mM of MgCl2, 1U of Long PCR 
Enzyme Mix (Thermo Scientific) and 10x Long PCR Buffer and approximately 120ng of 
DNA. The sequencing of the three gene fragments was done using ABI BigDye 
Terminator version 3.1 cycle sequencing chemistry (Life Technologies), and 
electrophoresis analysis was done on an ABI 3130 automated sequencer. All 
sequences were assembled and analysed using the Phred-Phrap-Consed package57. 
All putative polymorphisms and software-derived genotype calls were visually 
inspected and were individually confirmed using Consed. Details about sequencing 
primers are presented in Table A1 (Appendix). 
   
 
3.1.4 PCR and Microsatellite analysis 
Haplotype characterization of the SERPINA1 rare alleles included the analysis 
of two different microsatellites. A CAn repeat located 7.5 kb downstream of SERPINA1 
and a GTn repeat located 207 kb upstream of SERPINA1, as showed in Figure 9. The 
amplification of the two microsatellites was done using fluorescently labelled primers as 
previously described33. Microsatellite amplicons were separated by electrophoresis in a 
3130 ABI Sequencer and the analysis was done using Gene Mapper software (Life 
Technologies).  
Figure 8: Schematic representation of SERPINA1 amplification.  Upper lines 
show the SERPINA1 orientation in chromosome 14 long arm and lower lines shows 
the structure of the gene where exons are represented as full boxes and introns by 
lines. Large arrows indicate the regions surveyed for sequence variation (F1-F3).   
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Figure 9:  Location of the two microsatellites used in the haplotipic characterization of SERPINA1 rare alleles. 
  
3.1.5 Data analysis  
Haplotypes were inferred using the program PHASE 2.058, 59. To improve 
haplotype inference for microsatellite data we used haplotypes derived from two-
generations studies of Portuguese families33. 
 
3.1.6 Characterization of Q0Faro allele 
The synthesis of cDNA was performed by reverse transcription-polymerase 
chain reaction (RT-PCR) using the Superscript II RT-PCR system (Life Technologies, 
Gibco, BRL) and the manufacturers recommended conditions.  
Then we performed a PCR reaction to further elucidate the basis of the Q0Faro 
null allele using different primer combinations: IA/IIR; IC/IIR; IA/IIIR. The sequence of 
the primers are: IA, 5’- TCCTGTGCCTGCCAGAAGAG-3’; IC, 5’-
ATCAGGCATTTTGGGGTGACT-3’; IIR, 5’- CCACTAGCTTCAGGCCCTCGCTGAG -3’ 
IIIR, 5’- GATGATATCGTGGGTGAGAACATTT-3’.  
The cycling conditions for PCR were: 
- 94ºC 2min 
- 94ºC 10s, 58ºC 10s, 68ºC 2min 30s (10 cycles) 
- 94ºC 10s, 54ºC 10s, 68ºC 2min 30s plus 3s per cycle (30 cycles) 
- 68ºC 20min. 
Digestion  
 The DNA digestion was done during 20min at 37ºC with 1U of enzyme (RsaI 
and ECO91I; Thermo Scientific) per 1µL of amplified products. 
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3.1.7 SERPINA1 conservation 
Ortholog cDNA sequences for SERPINA1 were retrieved from the National 
Center for Biotechnology Information database (NCBI) (http://www.ncbi.nlm.nih.gov) 
and Ensembl (http://www.ensembl.org/) for the following mammalian species: human 
(Homo sapiens), common chimpanzee (Pan troglodytes), gorilla (Gorilla gorilla), 
orangutan (Pongo abelii), northern white-cheeked gibbon (Nomascus leucogenys), 
rhesus macaque (Macaca mulatta), baboon (Papio anubis), marmoset (Callithrix 
jacchus), mouse (Mus musculus), rat (Rattus norvegicus), dog (Canis familiaris), cat 
(Felis catus), cow (Bos taurus), pig (Sus scrofa), sheep (Ovis aries) opossum 
(Monodelphis domestica) and zebrafish (Danio rerio) (Table 2).  
We used CLUSTALW60 implemented in the MEGA561 software to align cDNA 
sequences. SERPINA1 alignments were used to construct phylogenetic trees using 
neighbour-joining method with 10000 bootstraps implemented in MEGA5. The ratio of 
non-synonymous and synonymous substitution rates (dN/dS = ω) was estimated using 
the maximum likelihood (ML) framework implemented in the program CODEML of 
Phylogenetic Analysis by Maximum Likelihood (PAML) software62. We used the site 
model test M3 (discrete selection model) to investigate the conservation and selective 
pressures that have shaped the evolution of SERPINA1. This model adopts 3 
categories of codon positions (sites) and assumes an unconstrained discrete 
distribution to model heterogeneous ω values among sites and detect codons evolving 
under different selective forces63. While values of ω>1 are considered as evidence of 
positive selection, values of ω<1 are regarded as proof of purifying selection 
(conservation). The Naive Empirical Bayes (NEB) approach is implemented to 
calculate the posterior probability for each amino acid site and detect conserved, 
neutral and positive selected codons62. 
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              Table 2:  Accession numbers for SERPINA1 cDNA sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 SERPINA2  
3.2.1 Samples 
 DNA samples from ZZ subjects were collect from different populations. These 
included 24 samples from Portugal, with a diagnosis of emphysema, COPD or AATD 
disease, 20 samples from Birmingham (England) with a diagnose of emphysema or 
COPD, and 10 samples from GPA patients, 5 from Birmingham and 5 from Bochum 
(Germany). 
3.2.2 PCR and DNA sequencing  
 The SERPINA2 was amplified in 3 fragments (Figure 10). The first comprising 
only the exon II, the second containing only exon III and the last fragment spanning 
exon IV and exon V. The amplification of the 3 fragments from the genomic DNA was 
carried using the cycling conditions described in Table A2 (Appendix) and the following 
reagents: 0.5 µM of each oligonucleotide, 200 µM of dATP, 200 µM of dTTP, 200 µM of 
Species Accession Number Database 
Homo sapiens NM_000295.4 NCBI 
Pan troglodytes ENSPTRT00000045369 
 
Ensembl 
Gorilla gorilla ENSGGOT00000007925 
 
Ensembl 
Nomascus leucogenys XM_004091842 
 
NCBI 
Macaca mulatta ENSMMUT00000039542 
 
Ensembl 
Callithrix jacchus ENSCJAT00000061674 
 
Ensembl 
Papio anubis XM_003902213 
 
NCBI 
Mus musculus ENSMUST00000085056 (serpina1a) 
1  
2  
3 ENSMUST00000164454 
4  
5  
 
Ensembl 
 ENSMUST00000164454 (serpina1b) 
 
 
Rattus norvegicus ENSRNOT00000012577 
 
Ensembl 
Canis familiaris ENSCAFT00000036554 
 
Ensembl 
Felis catus XM_006933076.1 NCBI 
Bos taurus NM_173882 
 
NCBI 
Sus scrofa ENSSSCT00000002750 
 
Ensembl 
Ovis aries ENSOART00000016196 
 
Ensembl 
Monodelphis domestica ENSMODT00000033265 
 
Ensembl 
Danio rerio NM_001077758 NCBI 
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dGTP, 200 µM of dCTP, 1U of Hot Star Taq (DNA polymerase from Qiagen), 10x buffer 
and about 100ng of DNA reaching 25 µL of final volume. After the amplification was 
completed the sequencing of the coding regions was done using the primers presented 
in Table A2 (Appendix).  
 
 
 
3.2.3 Cloning of SERPINA2 
 The cDNA corresponding to the V2 variant (Leu308-Glu320) of SERPINA2 from 
a previous SERPINA2/pLenti6V5 construct54 was amplified and fused to a stable His-
tag using the proofreading polymerase (Thermo Scientific), and specific primers (Fw: 
5’TTCCTGATGT^TCATCGCTTTCGTCATCATCGCTGAGGCCGAGGATCCCCAGGG
AGATGCTGCCCA3’; Rv: 5’CTACTGGCCA^ACCAACCCACCCTAAGTGGTGAA3’). 
The PCR product was then digested with BsaBI and AgeI enzyme (Bio Labs), 
respectively, using recommended conditions. The ligation of the insert into the pIEX5 
vector (Novagen) was done with T4 DNA ligase (Bio Labs). Later the SERPINA2/pIEX5 
construct was used in the SERPINA2 subcloning into the pTT5 vector (collaboration 
partner) using BamHI enzyme (Bio Labs).    
Figure 10: Schematic representation of SERPINA2 amplification.  Upper 
lines show SERPINA2 orientation in chromosome 14 long arm cluster and lower 
lines the structure of the gene where exons are represented as full boxes and 
introns by lines. Large arrows indicate the regions surveyed for sequence 
variation (F1-F3).   
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3.2.4 Transfection and protein extraction 
 The expression of SERPINA2 was done in two biological systems. The first 
SERPINA2/pIEX5 construct was used in the transfection of the Schneider S2 cells from 
Drosophila (Xiao Shell, EPFL, Lausanne) and the SERPINA2/pTT5 construct used for 
the transfection of human HEK293 cells.  
HEK293 cells (ATCC number CRL-1573) were grow in FreeStyleTM medium 
(Life Technologies) containing 24µg/ml of G418 (PAA Company) and 0.1% of Pluronic 
F68 (Life Technologies). The vector was transfected into HEK293 with OptiProTM SFM 
(Life Technologies) and polyethylenimine (PEI) (Sigma). After twenty four hours of 
transfection  Bacto TC Lactalbumin Hydrolysate (BD Biosciences) was added for a final 
concentration of 0,5%.        
After ninety six hours of transfection, expressed SERPINA2 in HEK293 cells 
was collected from cultured cell supernatants and concentrated in Amicon ultra 
centrifugal filters unit (EMD Millipore) with 1x elution buffer (EB) (20 mM Na2HPO4, 500 
mM NaCl pH 7,4) supplemented with 10mM imidazole. SERPINA2 was purified on 
nickel columns using the Ni-NTA Spin Kit (Quiagen), 1(x)EB with increase imidazole 
concentrations starting from 250mM. The purification of the supernatant from 
Schneider S2 cells started with overnight dialysis in 1(x)EB 10mM imidazole and then 
according to the protocol from Äkta Prime Plus from GE Healthcare and using the 
same buffer for sample loading  and for elution a imidazole gradient up to 1M. Then 
collected 13 purified fractions, and after that concentrated the elution fractions of 
interest in Amicon ultra centrifugal filters unit (EMD Millipore) using 1(x)EB without 
imidazole. 
  
3.2.5 Western blot 
 The total protein concentration of cell supernatants was determined by Bio-Rad 
protein assay. Protein (approximately 5 µg) were mixed into 10(x)gel loading buffer, 
heated at 95ºC for ~5min, and separated by SDS-PAGE (12% poly-acrylamide). For 
the immunodetection of SERPINA2, the protein was transferred to a nitrocellulose 
membrane, blocked in phosphate buffer solution with Tween 20 (PBS-T) and 5% 
blocking non-fat milk solutions, and then probed with two antibodies. A first antibody 
against SERPINA2 G-12 (Santa Cruz Biotechnology) diluted in PBS-T at a 1:500 ratio, 
and another against the stable His-tag anti-His 3D5 diluted at a 1:2500 ratio (Dr. 
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Elisabeth Kremmer, HMGU). In the first anti-IgG HRP (Chemicon) diluted at 1:1000 
and in the second case the secondary antibody goat anti-mouse HRP (Pierce) diluted 
at a 1:5000 ratio was used.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.Results and Discussion 
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4.1 SERPINA1 mutational spectrum 
     4.1.1 Rare alleles causing AATD 
 The sequencing study of 51 cases of AATD allowed the identification of 13 
mutations in SERPINA1 gene distributed by 14 rare deficient or null alleles (Table 3)32. 
All cases of AATD were previously analysed by isoelectric focusing (IEF), which 
warranted the evaluation of the mobility of the rare allele in the protein gel 
electrophoresis, as well, as the comparison of its band intensity with non-deficient 
alleles (M1, M2, M3 and M4) .  
 Among the 13 mutations identified, 5 were novel (Glu162Gly, Leu263Pro, 
Arg281framStop297, Met374framStop392 and IVSIC+3Tins) and described for the first 
time in the Portuguese population (Table 3). Therefore, those alleles carrying the novel 
mutations were named accordingly to the protein pattern in IEF gels and the place of 
birth of the index case. Importantly, three of these rare alleles were found in the index 
case in heterozygosity with common deficient alleles (S and Z) confirming the clinical 
classification as cases with severe AATD.      
      Table 3: Rare alleles of SERPINA1associated with AATD identified in the current work 
Allele Mutation Molecular base 
Relative 
frequency 
Previously described 
MMalton Phe52del M2 17/51(0.333) 
MPalermo Phe52del M1Val213 9/51(0.176) 
I Arg39Cys M1Val213 7/51(0.137) 
Q0Ourém L353fsX376 M3 4/51(0.078) 
PLowell Asp256Val M1Val213 3/51(0.059) 
MHerleen Pro369Leu M1Val213 3/51(0.059) 
MWurzburg Pro369Ser M1Val213 1/51(0.020) 
Q0Lisbon Thr68Ile M1Val213 1/51(0.020) 
T Glu264Val S 1/51(0.020) 
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In addition, two other rare mutations were identified in the course of this 
sequencing study (Ser47Arg and Val302Ile) however, none of them could be 
associated to AATD. 
        4.1.1.1 Novel mutations 
       4.1.1.1.1 Amino Acid substitutions 
Leu263Pro (Q0Gaia) 
The variant Q0Gaia is characterized by a Leu(CTG)Pro(CCG) mutation at 263 
residue, which was identified in heterozygosity with a Z allele in two siblings with lung 
disease. This mutation is likely to have serious repercussions in SERPINA1 structure 
has indicated by the absence of a corresponding band in protein gel electrophoresis. 
The Leu263 residue is highly conserved among SERPINA1 orthologs (placental 
mammals) (Figure 11) and within the SERPIN superfamily LeuPro and ProLeu 
substitutions are known to cause drastic alterations in the three dimensional 
structure18. Interestingly, the Leu263Pro is next to the residue Glu264, which underlies 
one of the common deficiency alleles when replaced by a valine residue (S allele). 
Likewise, the substitution of Leu263Pro is also likely to cause the distortion of the G α-
helix (Figure 12) and affect the gate domain as it happens with Glu264Val 
substitution18.  
 
 
Allele Mutation Molecular base Relative frequency 
Novel mutations 
Q0Gaia Leu263Pro M1Ala213 1/51(0.020) 
PGaia Glu162Gly M1Val213 1/51(0.020) 
Q0Oliveira do Douro Arg281framStop297 M3 1/51(0.020) 
Q0Vila Real Met374framStop392 M3 1/51(0.020) 
Q0Faro IVSIC+3Tins M1Val213 1/51(0.020) 
Table 3: (Cont.) 
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Glu162Gly (PGaia) 
The variant PGaia is characterized by a Glu(GAG)Gly(GGG) mutation at 162  
codon, which was firstly identified by a distinctive mobility band in protein gel 
electrophoresis (Figure 13). This variant was identified in a single patient with lung 
emphysema in heterozygosity with an S allele. The Glu162 residue is located in the 
SERPINA1 F α-helix (Figure 12) and it is highly conserved among SERPINA1 
orthologs (Figure 11). Moreover, bioinformatics predictions by Polyphen-2 
(http://genetics.bwh.harvard.edu/pph2/) suggest the Glu162Gly substitution as a 
damaging mutation possibly affecting SERPINA1 structure. 
 
Figure 11: Sequence alignment of SERPINA1 orthologs. Conserved Glu162 and Leu263 residues are highlighted. 
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Glu162Lys 
Leu263Pro 
 
 
  
 
This category of mutations, causing the substitution of an amino acid in protein 
sequence, are usually named as non-synonymous or missense mutations. These have 
different effects depending on the biochemical properties of the residues implicated in 
the substitution and their location in protein structure. In the particular case of 
Leu263Pro and Glu162Gly although, we did not proceed for a functional 
characterization of the mutant alleles (Pro263 and Gly162) the evidences collected so 
far point to a pathogenic effect of both mutations. First, these mutations were identified 
in patients with lung emphysema and reduced serum levels of SERPINA1. Second, the 
two mutations occur in highly conserved residues among SERPINA1 orthologs (Figure 
11). Third, the Q0Gaia allele lacked a corresponding protein band in the M region and 
the PGaia showed a band with similar intensity to S deficient allele (Figure 13).  
Furthermore, several examples from the literature show that other LeuPro 
substitutions like Leu263Pro and even ProLeu replacements are associated with 
severe distortions in protein structure. This is the case of SERPINA1 MProcida 
(Leu41Pro) and alpha-1-antichymotrypsin (SERPINA3) Bochum-1 (Leu55Pro) alleles, 
in which the introduction of a proline instead of a leucine distorts A and B SERPIN α-
helices, respectively18,64. While in the MProcida allele, the Leu41Pro substitution causes a 
drastic  reduction in SERPINA1 serum levels (~96%)65 due to its intracellular 
degradation prior to secretion64, in the Bochum-1 variant the Leu55Pro replacement 
has been correlated to both SERPINA3 deficiency and decreased inhibitory activity18.  
On the other hand, in the MHeerlen (Pro369Leu) allele the replacement of a 
proline by leucine was found to disrupt another α-helix causing a severe reduction in 
Figure 12: Three dimensional structure of SERPINA1. The location of 
the two novel mutations in SERPINA1 is indicated. The amino acid 
substitution Leu263Pro (Q0Gaia) is shown in blue and the substitution 
Glu162Lys (PGaia) is shown in magenta. 
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protein levels (~98%), in result of the protein transport blockage between ER and the 
Golgi apparatus18, 66. As a whole these four mutations seem to produce misfolded 
proteins possibly recruited for intercellular degradation and poorly secreted from the 
cells18. Such functional effects on SERPINA1 structure are likely to be correlated with 
biochemical properties of the two residues, while leucine is a hydrophobic residue 
displaying a preference for -helices, the proline is a small amino acid with unique 
properties and the ability to introduce kinks in -helices67. 
  So far no other GluGly mutation has been described for SERPINA1, 
nevertheless two deficiency alleles were found to involve the GlyGlu substitutions 
(Gly67Glu and Gly320Glu). Taking into account the different properties of glycine and 
glutamic acid residues the Glu162Gly mutation is expected to have serious 
repercussions in SERPINA1 structure. Glycine is a small neutral residue that may 
adopt many conformations and frequently found in protein positions with space 
limitations. Conversely, the glutamic acid is a polar and negatively charged amino acid 
with a larger side chain with a preference to expose its charged chain to the solvent. In 
particular case of Gly67Glu mutation the B α-helix is affected causing abnormal 
posttranslational biosynthesis and reduced SERPINA1 secretion68. The implications of 
the Gly320Glu mutation are not well understood since it was been identified in a null 
allele also bearing a Z mutation (Glu342Lys).    
   
 
 
 
Figure 13: Electrophoretic patterns of PGaia and common SERPINA1 alleles.  The phenotypes from samples 
1 to 9 are as follows: 1, 4 and 5 - M1; 2 and 6- M2Z; 3 and 7- SPGaia; 8- M1M3 and 9-SZ.     
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     4.1.1.1.2 Small Deletions 
Arg281framStop297 (Q0Oliveira do Douro) 
The null allele Q0Oliveira do Douro results from a 2 bp deletion (GA) in 281 codon  
(Figure 14A), causing an alteration of the reading frame (frameshift mutation) and a 
premature termination codon at position 297 (Arg281framStop297) (Figure 14B). The 
Q0Oliveira do Douro variant was identified in a single Portuguese family with AATD, where 
the index case was a child heterozygous for the S allele with asthma and AATD. This 
mutation is likely to affect the mRNA processing or the stability of the truncated protein 
as indicated by the absence of a corresponding band in the IEF gel.      
 
 
Met374framStop392 (Q0Vila Real) 
The null allele Q0Vila Real results from a 4 bp deletion (ATGA) affecting 374 and 
375 codons (Figure 15A) which causes a frameshift and leads to a premature 
termination codon at position 392 (Met374framStop392) (Figure 15B) a few bases 
upstream of the canonical SERPINA1 stop codon (395). The Q0Vila Real variant was 
identified in an asymptomatic child displaying reduced serum levels of SERPINA1 
(heterozygous for the M allele). Like in the previous mutation no protein band could be 
associated to this allele suggesting an associated mechanism of the mRNA or protein 
degradation.   
Figure 14: Q0Oliveira do Douro allele. A – Electropherogram of the index case. The arrow 
shows the region of GA deletion. B – Reading frames of M and Q0Oliveira do Douro 
alleles.  
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The category of small deletions causing shifts in the gene reading frame and 
the insertion of a premature termination codon can imply a significant reduction of the 
mRNA transcripts levels. In general, frameshift mutations occurring in early or mid 
phases of coding regions are linked to a decreased steady-state of cytoplasmic mRNA. 
Apparently, premature terminated transcripts interrupt the mRNA pulling process and 
lack important elements of canonical stop codons, which turn mRNA molecules 
vulnerable to RNase digestion. This process of mRNA degradation avoiding the 
accumulation of abnormal transcripts and proteins is called nonsense mRNA decay 
(NMD). However, if the introduction of premature stop codons happens near the 
regular termination region the mutant allele might not be target to NMD and be linked to 
normal mRNA levels69.  
 The two allele described above introduce premature stop codons in different 
regions of SERPINA1, while the Q0Oliveira do Douro allele carries a premature stop codon in 
the beginning of exon IV,  Q0Vila Real allele has a termination codon four triplets 
upstream of SERPINA1 termination. Although, we lack experimental data to confirm 
our hypothesis, we expect Q0Oliveira do Douro to lack the presence of any transcripts due to 
the degradation by NMD. In contrary the Q0Vila Real we would expect to detect normal 
transcript levels and possibly an abnormal protein rapidly eliminated by intracellular 
pathways of protein degradation. Indeed, this is the case of Q0Matawa another 
SERPINA1 variant resulting from a frameshift mutation causing a premature 
termination at 376 codon70.        
Figure 15:  Q0Vila Real allele. A – Electropherogram of the index case. The arrow 
shows the region of ATGA deletion. B – Reading frames of M and Q0Vila Real alleles. 
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         4.1.1.1.3 Splice site mutation 
    IVS1C+3Tins (Q0Faro) 
The null allele Q0Faro is characterized by the occurrence of an insertion of a 
thymine at the +3 position in intron IC (Figure 16). This variant was identified in a single 
Portuguese family with AATD and the index case was an asymptomatic child displaying 
reduced SERPINA1 serum levels (heterozygous for M allele). 
 
SERPINA1 has different transcription starting sites, which vary according to cell 
type. Whereas in hepatocytes the transcription starts within the exon IC, mononuclear 
phagocytes use specific initiation sites located in exons IA and IB. Importantly, 
mononuclear phagocytes exhibit alternative splicing of exons IA, IB and IC generating 
14 transcripts. These mRNAs may be divided into three general isoforms IA-IB-IC-II, 
IA-IC-II and IA-II (Figure 17A) and two of these isoforms may be further subdivided 
according to the use of cryptic splice sites located in exon IB and IC (Figure 17B). 
Transcripts containing IB exon may differ by 18bp at 3’-end of exon and RNA products 
including IC exon can vary by the presence or absence of an additional CAG triplet in 
5’ start (Figure 17B) 32,71.   
 
Figure 16. Electropherogram of Q0Faro allele. The arrow shows the 
insertion of a thymine in intron IC.  
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The Q0Faro represents a rare example of a mutation in a 5’ untranslated region 
(UTR) of SERPINA1, in the donor splice site of exon/intron IC. Only another pathogenic 
mutation was identified in the same region and in that case it affected the first base of 
the intron IC. The allele named Q0Porto was found to produce a single transcript in 
mononuclear phagocytes (IA-II transcript), which did not use the IC donor splice site. 
Such finding explained the absence of the protein in the serum since in the 
hepatocytes, the mRNA transcription was abolished. To evaluate whether Q0Faro had a 
similar effect to those of Q0Porto we performed a characterization of the different 
transcripts from mononuclear phagocytes in the index case (M1AlaQ0Faro) and the 
parent carrying the mutated allele (M2Q0Faro).   
We performed several experiments that included the analysis of the 
mononuclear phagocytes cDNA by PCR amplification of three different fragments 
covering: IA-II exons (IA/IIR); IA-II-III exons (IA/IIIR) and IC-II exons (IC/IIR); in a 
similar methodological approach to the one used for the description of Q0Porto
72. Taking 
into account the M1Val213 molecular base of Q0Faro allele we used Arg101His (exon II) 
and Ala213Val (exon III) polymorphisms to discriminate the wild type alleles (M1Ala 
and M2) from the mutated Q0Faro allele. In the index case M1AlaQ0Faro, the Ala213Val 
polymorphism was used to discriminate between the two alleles and in the M2Q0Faro 
the Arg101His polymorphism was used instead (Table 4, see also Figure 3). 
Figure 17: Alternative SERPINA1 transcripts (14n) of mononuclear phagocytes. A – mRNA transcripts resulting from 
the alternative splice of IA; IB and IC exons. B – mRNA transcripts resulting from the use of cryptic splice sites in 3’-end 
of exon IB and at 5’ of exon IC. (Figure from Rollini et al.
71
)    
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Table 4: Molecular base of Q0Faro, M1Ala213 and M2 alleles. 
 SERPINA1 polymorphism 
Allele Arg101His (exon II) Ala213Val (exon III) 
Q0Faro Arg Val 
M1Ala213 (index case) Arg Ala 
M2 (parent) His Val 
 
 The evaluation of the Q0Faro allele was carried out using two restriction 
enzymes specific for each polymorphism, for Arg101His we used RsaI which 
recognizes Arg101 codon and for Ala213Val we used ECO91I which digest Val213 
codon. Figure 18A shows the RsaI restriction pattern obtained in the IA/IIR fragment for 
M1Q0Faro and M2Q0Faro samples. The presence of a 496 bp fragment generated by 
RsaI (Arg101) in the parent (M2Q0Faro; lane P), together with another fragment of 570 
bp (His101) confirms the existence of IA-II transcripts in both wild type (M2) and 
mutated (Q0Faro) alleles. This finding was also confirmed in the index case 
(M1AlaQ0Faro), in the IA-IIIR fragment with ECO91I enzyme, which also displays a 
heterozygous restriction pattern (Figure 18B) consistent with the presence of IA-II 
transcripts in both alleles. Conversely, the same was not observed in the RsaI 
restriction pattern for IC/IIR fragment (Figure 18C) where no band corresponding to 
Q0Faro (Arg101) was in the M2Q0Faro subject (lane P). These results confirm a similar 
effect of the novel mutation IVS1C+3Tins (Q0Faro allele) to the previously described 
mutation of the Q0Porto allele (IVS1C-1GA). The insertion of a thymine at +3 base of 
intron IC and the substitution G to A at +1 base of intron IC both disrupt the donor 
splice of exon IC. In the hepatocytes these mutations abolish the regular transcription 
of SERPINA1 and consequently no protein is secreted into the bloodstream. 
Nevertheless, other cell types like mononuclear phagocytes may secrete SERPINA1 
due to the presence of the upstream transcription start site in exon IA and an 
alternative splicing transcript that does not requires the use of exon/intron IC junction 
as donor splice site (Figure 19). However, the SERPINA1 produced by those cells is 
expected to have a residual impact in the protein serum levels not enough to avoid the 
clinical outcomes of AATD. These mutations located outside of SERPINA1 coding 
region (exon II-V) highlight the importance of surveying the UTR in particular 
exon/intron IC region in cases of unexplained AATD.   
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Figure 18: Detection of Arg101His and Ala213Val variation in the cDNA from mononuclear phagocytes of the 
two Q0Faro subjects. A – PCR products amplified with primer pairs IA/IIR and digested with Rsa I restriction enzyme. 
The restriction enzyme recognizes Arg101 residue and generates a fragment of 496bp; B – PCR products amplified with 
primer pairs IA/IIIR and digested with ECO91I restriction enzyme. The ECO91I recognizes the Val213 and generates 
two fragments of 209 and 1079bp; C – PCR products amplified with primer pairs IC/IIR and RsaI enzyme. The restriction 
enzyme recognizes Arg101 residue and generates a fragment of 465bp . I – Index case; (M1AlaQ0Faro); P- Parent, 
(M2Q0Faro); A- amplicon for each primer combination. MW- Molecular weight. 
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Figure 19: Schematic representation of SERPINA1 alternative splicing as deduced from the exon composition 
of mRNA species produced by mononuclear-phagocytes in M alleles and Q0Faro and Q0Porto. M- mononuclear-
phagocytes transcription starting sites; H-hepatocytes transcription starting site. (Adapted from Seixas et al.
72
).   
 
   
4.1.1.2 Previously described mutations 
Phe52del (MPalermo and MMalton) 
The MPalermo (Mpa) and MMalton (Mm) are two rare variants characterized by a 
deletion of a phenylalanine codon (TTC) at position 52 (exon II) and while the MPalermo is 
associated to a M1Val213 molecular base, the MMalton is linked to a M2 allele instead. 
The Phe52del mutation is associated with severe AATD due to the intracellular 
accumulation of SERPINA1 in the ER, and to a dramatic reduction in the serum 
(<10%). This suggests for Phe52del and Glu342Lys (Z allele) a similar 
pathophysiological model of AATD. Indeed, the Phe52del mutation also favors the 
formation of loop-sheet polymers, which cause the formation of hepatic inclusions even 
in heterozygosity with non-deficiency alleles73.   
At the protein level, the Phe52del mutation causes the removal of a residue with 
strong hydrophobic aromatic side chains in the core center of the molecule, which is 
also a highly hydrophobic region. This amino acid removal perturbs the molecular 
conformation and folding of SERPINA1 and its later maturation in the Golgi apparatus 
and secretion29,74. 
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 The Phe52del mutation and the MPalermo and MMalton alleles represent the most 
widespread rare variants underlying cases of AATD in Portugal (Table 3), which have 
also been identified elsewhere in Europe.  
The haplotype characterization of MPalermo and MMalton using the combination of 
both sequence and microsatellite variation data (Table 5) reinforces the previous 
findings of an origin of Phe52del mutation in two distinct molecular backgrounds32. In 
addition, the detection of intrahaplotipic variation among MPalermo sequences but not 
within MMalton, suggest MPalermo as a more ancient allele because it had already enough 
time to recombine at the 5’ SERPINA1 region.         
Arg39Cys (I) 
The I allele is a mild deficiency variant characterized by a 
Arg(CGC)Cys(TGC) substitution in codon 39. This amino acid replacement is a 
functional equivalent of Glu264Val mutation (S allele) since it also disrupts the 
hydrogen bond stabilizing SERPINA1 G α-helix. Likewise, it is associated to 50-60% of 
normal serum levels and some level intracellular polymerization in the ER which may 
contribute to hepatic damage in IZ heterozygous18,75. The Arg39Cys is one of the most 
prevalent rare mutations in Europe and in our cohort of rare alleles causing AATD in 
Portugal. The haplotype analysis of I chromosomes showed reduced variation at the 
sequence level (M1Val213 base allele) and a considerable diversity in the 
microsatellite located approximately ~207 kb upstream of SERPINA1 (Table 5). These 
results suggest a single origin of Arg39Cys mutation old enough to have spread 
throughout Europe and to have recombined with other alleles increasing the linked 
variation in the CAn microsatellite and in the promoter region of the gene.          
 
Leu353framStop376 (Q0Ourém) 
The Q0Ourém (Q0O) is a rare null variant characterized by an insertion of an extra 
thymine in a stretch of 5 thymines between codons 352-353, which alters the reading 
frame starting at codon 353 and ending in codon 376 (Leu353framStop376), with a 
premature stop codon (TGA). This variant was identified in several families from 
Central Portugal and differs in its molecular background from another rare variant 
Q0Mattawa, found in two compound heterozygotes from Canada. Whereas the Q0Ourém 
has been always associated to M3 allele the Q0Mattawa was identified in a M1Val213 
background70. This evidence together with the geographical dispersion of the two 
alleles suggests an independent origin of the Leu353framStop376 mutation, possibly 
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correlated with an increase mutational rate at codons 352-353 due to slippage-
mispairing72. The timing for the origin of Q0Ourém mutation was estimated in the middle 
ages approximately 650 years ago. In this study, the Q0Ourém variant was identified in 
three additional cases including one in homozygosity, all from different regions in 
Portugal with no apparent familial relationship with previous described cases. 
Interestingly, an occurrence of a Q0Ourém outside of Portugal was already acknowledge 
in La Palma (Spain)76, which reinforces the hypothesis of Q0Ourém being much older 
than initially thought. The haplotype characterization of the recently identified alleles 
and their comparison with the published data (microsatellite only) shows at least a 
novel haplotype configuration (B10-P7), which was not observed in the other 
Portuguese families (Table 5)24.  
The Q0Ourém is the most prevalent SERPINA1 null allele in Portugal and it may 
underlie extreme cases of AATD due to the nearly absence of SERPINA1 in the serum. 
Like Q0Vila Real and Q0Matawa, the Q0Ourém is likely to be transcribed and translated into 
unstable protein rapidly eliminated by the ER intracellular degradation.      
Asp256Val (PLowell) 
The PLowell (Pl) allele is another mild deficiency variant associated to 30% of 
normal serum levels, which is defined by a Asp(GAT)Val(GTT) substitution in 256 
codon. This mutation causes the loss of a salt bridge (Asp256 to His231) directing the 
newly synthesized SERPINA1 to intracellular degradation by the liver cells18. The PLowell 
allele has been reported in different European populations and in Portugal it was found 
in several instances among cases of AATD. The haplotype analysis of the three PLowell 
chromosomes identified in our cohort revealed an M1Val213 molecular basis and some 
variability at both sequence and microsatellite levels (Table 5). 
 
Pro369Leu (MHerleen) and Pro369Ser (MWurzburg) 
The MHerleen (Mh) and MWurzburg (Mw) are two rare variant of severe deficiency 
both affecting codon 369 and firstly described in Central Europe. The MHerleen is 
characterized by a Pro(CCC)Leu(CTC) mutation in a M1Ala213 background, which 
could be associated to a reduction of protein secretion of ~98%. As mentioned before, 
in the SERPIN family the replacement of a proline by leucine has serious 
repercussions in protein structure. In case of Mh the Pro369Leu protein was found to 
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be retained in the ER of transfected mammalian cell lines however, no evidence of 
SERPINA1 accumulation was detected in mice models or in MHerleen carriers
66.  
In the MWurzburg (Mw) allele the Pro369 (CCC) is replaced by a Ser (TCC), which 
leads to a 80% reduction in SERPINA1 serum levels due to the intracellular 
accumulation of protein in the endoplasmic reticulum66. These two variants illustrate 
well the impact in SERPINA1 of newly introduced residues with different biochemical 
properties, while the substitution of the proline by leucine seems to produce a drastic 
effect on SERPINA1 structure possibly targeting the MHerleen protein for intracellular 
degradation, the replacement of the proline by a serine appears to be tolerated (or 
escape quality control mechanisms) leading to MWurzburg polymerization in 
hepatocytes77. Consequently, the MWurzburg allele is associated with an increased risk of 
both pulmonary and hepatic diseases66,77, whereas the MHerleen is only associated with a 
risk of pulmonary disease66. 
Interestingly, the haplotype characterization of the two MHerleen chromosomes 
showed that in both cases the Pro369Leu was linked to an M1Val213 molecular base 
instead of the previously described M1Ala213. The single MWurzburg chromosome was 
also linked to a M1Val background allele (Table 5).  
 
Thr68Ile (Q0Lisbon)  
The Q0Lisbon (Q0l) allele is another variant of severe deficiency found in few 
families with Portuguese ancestry, characterized by a Thr(ACC)Ile(ATC) substitution 
in 68 codon. This substitution is likely to affect the configuration of SERPINA1 B -helix 
leading to an unstable protein rapidly eliminated by the cells66. 
 
Glu264Val (T)  
The T allele is a rare variant that could be identified as the occurrence of the 
Glu264Val substitution in a M2 molecular base instead of the M1Val213 as observed in 
the S allele. However, the haplotype characterization of the single T chromosome 
found in our cohort of rare alleles disclosed a higher sequence similarity to S 
chromosomes rather than to M2 alleles (Figure 20). Indeed, the T allele only differed 
from S chromosomes by the presence of an aspartic acid in 376 position (see also 
Figure 3). Therefore, two alternative hypotheses for the origin of T allele can be 
advanced, or the T allele arose from a recombination event between S and a M2 or M3 
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(Asp376) chromosomes; or on the other hand, it originated from the recurrences of 
Glu376Asp in S molecular base. The association of the T variant to a P4 allele at GTn 
microsatellite located 7.5 kb downstream SERPINA1, which is more frequent among S  
than in M2 or M3 chromosomes33 points the second hypothesis as more probable 
(Figure 20). However, this may not be the single mechanism of origin for T allele since 
in at least another case the T variant was linked to a different haplotype32. 
 
    
Rare alleles not linked to AATD (Ser47Arg  and Val302Ile) 
  In the current work, we identified two other rare mutations associated to normal 
serum levels. A S-like allele resulting from a Ser(AGC)Arg(CGC) substitution in 47 
codon and a M-like variant caused by a Val(GTC)Ile(ATC) in 302 codon. The variant 
Ser47Arg has been previously described in populations with African ancestry (South 
Africa) without an association to AATD. Despite no pathogenic effects has been 
reported for Ser47Arg this amino acid replacement occurs in an N-glycosylation site 
Asn-Ser-Thr (46, 47 and 48 residues). Nevertheless, major changes in the 
glycosylation process would only be expected if residues 47 was replaced by a 
proline32,78,79. The variant Val302Ile was never report and bioinformatics predictions 
also reject the hypothesis of a pathogenic variant.  
 
 
 
Figure 20: Origin of T variant from S and M2 or M3 alleles. Observed haplotypes for the T, S, M2 and M3 alleles. The 
crossed lines indicate the possible region of recombination between S and M2 or M3 chromosomes.  
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Table 5: Haplotipic characterization of common and rare alleles. 
Ancestral 
Haplotype
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e
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3
7
6
A
s
p
CAn
B13 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P10
B7 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P4
B2 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P8
B2 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P4
B13 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P4
B12 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P8
B11 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P8
B6 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P8
B13 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P4
B12 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P11
B6 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P8
B11 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P8
B11 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P8
B13 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P8
B10 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P2
B12 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G C G G A C C G C P11
B11 C T T C G G A T A A C G A G C A - C A C A G T C T G T A T A T A G T T G G T G G A C C G C P8
B7 C T T C G G A T A A C G G A C A - C G C A A T C C G T A T A T A G T C A G C G G A C C G A P5
B2 C T T C G G A T A A C G G A C A - C G C A A T C C G T A T A T A G T C A G C G G A C C G A P5
B1 C T T C G G A T A A C G G A C A - C G C A A T C C G T A T A T A G T C A G C G G A C C G A P5
B13 C T T C G G A T A A C G G A C A - C G C A A T C C G T A T A T A G T C A G C G G A C C G A P5
B2 C T T C G G A T A A C G G A C A - C G C A A T C C G T A T A T A G T C A G C G G A C C G A P5
B6 C T T C G G A T G A C G G G C A - C G C A A T C C G T A T A T A G T C A G C G G A C C G A P6
B6 C T C C G G A T A A C G G G C A - C G C A A T C C G T A T A T A G T C A G C G G A C C G A P6
B6 C T T C G G A T A A C G A G C A - C G C A A T C C G T A T A T A G T C A G C G G A C C G A P11
B6 C T T C G G A T A A C G G G C A - C G C A A T C C G T A T A T A G T C A G C G G A C C G A P6
Mm
Mpa
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Table 5: (Cont.) 
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Haplotype
G C C C G G C C A A C A G G C A T C G C A G C C C G G A C A T A G T C G C G G G A C C G A
GTn
A
rg
3
9
C
y
s
S
e
r4
7
A
rg
P
h
e
5
2
d
e
l
T
h
r6
8
Ile
A
rg
1
0
1
H
is
G
lu
1
6
2
G
ly
V
a
l2
1
3
A
la
A
s
p
2
5
6
V
a
l
L
e
u
2
6
3
P
ro
G
lu
2
6
4
V
a
l
A
rg
2
8
1
fra
m
V
a
l3
0
2
Ile
G
lu
3
4
2
L
y
s
L
e
u
3
5
3
fra
m
P
ro
3
6
9
S
e
r
P
ro
3
6
9
L
e
u
M
e
t3
7
4
fra
m
G
lu
3
7
6
A
s
p
CAn
B13 C T T C G G A T A A C G A G T A T C G C A A T T C G T A T A T A G T C A G C G G A C C G A P11
B10 C T T C G G A T G A C G A G T A T C G C A A T T C G T A T A T A G T C A G C G G A C C G A P11
B12 C T T C G G A T A A C G A G T A T C G C A A T T C G T A T A T A G T C A G C G G A C C G A P11
B10 C T T C G G A T A A C G A G T A T C G C A A T T C G T A T A T A G T C A G C G G A C C G A P11
B7 C T T C G G A T A A C G A G T A T C G C A A T T C G T A T A T A G T C A G C G G A C C G A P11
B7 C T T C G G A T A A C G A G T A T C G C A A T T C G T A T A T A G T C A G C G G A C C G A P11
B6 C T C T G G A T A A C G A G T A T C G C A A T T C G T A T A T A G T C A G C G G A C C G A P11
B7 C T T C G G A T A A C G A G C A T C G C A G T C T G T A T A T A G T T G G T G G T C C G C P4
B7 C T T C G G A T A A C G A G C A T C G C A G T C T G T A T A T A G T T G G T G G T C C G C P4
B10 C T T C G G A T A A C G A G C A T C G C A G T C T G T A T A T A G T T G G T G G T C C G C P7
B10 C T T C G G A T A A C G A G C A T C G C A G T C T G T A T A T A G T T G G T G G T C C G C P7
B13 G C C T G A C C A A C G G G C A T C G C A A T C C G T A T T T A G T C A G C G G A C C G A P2
B12 G C C T G A C C A A C G G G C A T C G C A A T C C G T A T T T A G T C A G C G G A C C G A P2
B10 G C C T G A C C A A C G A G C A T C G C A A T C C G T A T T T A G T C A G C G G A C C G A P3
B13 C T T C G G A T A A C G A G C A T C G C A A T C C G T A T A T A G T C A G C G G A C T G A P4
B7 C T T C G G A T A A C G A G C A T C G C A A T C C G T A T A T A G T C A G C G G A C T G A P5
B6 C T T C G G A T A A C G A G C A T C G C A A T C C G T A T A T A G T C A G C G G A C T G A P6
Mw B5 G C C T G A C C A A C A G G C A T C G C A A T C C G T A T A T A G T C A G C G G A T C G A P8
Mh
I
Q0O
Pl
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Ancestral 
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Q0Gaia B12 C T T C G G A T G A C G G G C A T C G C A A T C C G T A C A C A A C C A G T G A A C C G A P10
PGaia B12 G C C T G A C C A A C G G G C A T C R C G A T C C G T A T A T T G T C A G C G G A C C G A P4
Q0OD B7 C T C C G G C C A A C A G G C A T C R C A A T C C G T A C A T A A C C A G C G G A C C G A P9
Q0VR B12 C T T C G G A T A A C G A G C A T C R C A G T C T G T A T A T A G T T G G T G G A C C T C P7
Q0F B7 G C C T G A C C A T C G G G C A T C G C A A T C C G T A T A T A G T C A G C G G A C C G A P6
Table 5: (Cont.) 
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 3.1.2 Mutational spectrum of SERPINA1 
 
Nowadays, the availability of large genomic databases comprising the  
complete sequence or the exome sequence of a few dozen or a thousand individuals 
from different population backgrounds (1000 Genomes project; NHLBI GO Exome 
Sequencing Project; ESP; etc), allows an in-depth analysis of the mutational spectrum 
for a gene of interest. In the particular case of SERPINA1 it was possible to compile a 
total of 100 mutations including those described in this work, other pathogenic mutation 
reported in the literature and novel variants identified in control populations (Table 6). 
Among these 35 mutations were clearly not associated with AATD, and were classified 
as non-pathogenic. However, in many cases especially in those identified in large 
genomic databases (25 mutations) we lack information about the association to AATD 
and therefore those were labelled as possibly or probably damaging according with 
bioinformatics predictions. Worth to note the Met358Arg substitution is not directly 
associated to AATD, but since it alters the protease affinity of SERPINA1 causing a 
gaining of a potent antithrombin activity it was classified as altered function. 
Nevertheless, this mutation may also considered as pathogenic given it causes serious 
homeostatic imbalances and it is associated with hemorrhagic fatal disease80. The 
remaining 39 mutations were identified in clinical cases and are implicated in mild or 
severe AATD, and thus were classified as pathogenic mutations. 
Interestingly, in the large genomic surveys of control populations a few 
pathogenic mutations were detected, which included the Arg39Cys (I allele), the 
Asp256Val (PLowell), Pro369Leu (MHeerlen) and the Pro396Ser (MWurzburg), which confirms 
that these are low frequency variants (0.1 – 1%) segregating within populations of 
European descended. On the other hand, the Q0Ourém (Leu353framStop376), Q0Lisbon 
(Thr68Ile) and the novel mutations identified in the current work are likely to be 
confined to Portugal or the Iberian Peninsula and possibly these are also more recent 
alleles that did not had enough time to spread throughout the European continent. 
Conversely, the Phe52del (MMalton and MPalermo) mutation, which is the most prevalent 
rare variant among our cohort of AATD cases was not identified in the genomic 
databases, possibly suggesting a very low frequency in control populations (>0.1%) 
and a higher risk of developing clinical symptoms associated to AATD. 
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Allele Mutation 
DNA 
sequenceb 
African 
descended 
European 
descended 
Asian 
descended 
Repercussions Project 
 Pro-23Leu CCGCTG 0.000 
  
Possibly damaging ESP 
ZWrexham Ser-19Leu TCGTTG 0.000 0.000  Non-pathogenic ESP 
 Trp-18Cys TGGTGT 0.000 
  
Probably damaging ESP 
 Leu-13Met CTGATG 
 
0.000 
 
Probably damaging ESP 
VMunich Asp2Ala GATGCT    Non-pathogenic  
 Thr13Ala ACAGCA 
 
0.009 
 
Non-pathogenic HapMap 
 His15Asn CACAAC 
 
0.000 
 
Non-pathogenic ESP 
 His16Arg CATCGT 
   
Non-pathogenic 1000GENOMES 
M5Karlsruhe Ala34Thr GCCACC 0.000   Non-pathogenic ESP 
Q0Knowloon Tyr38Stop TACTAA    
AATD: protein 
absence  
I Arg39Cys CGCTGC 0.001 0.002 
 
AATD: protein 
deficiency (60%) 
ESP, 
1000GENOMES 
MProcida Leu41Pro CTGCCG    
AATD: protein 
deficiency (4%)  
MVarallo 
Leu41-Phe51delfram 
Stop70-71 
    
AATD: Protein 
absence 
 
 His43Gln CACCAG 1.000 1.000 
 
Non-pathogenic ESP 
M6Bonn Ser45Phe TCCTTC  0.000  Possibly damaging ESP 
SLisbon Ser47Arg AGCCGC    Non-pathogenic  
Table 6: SERPINA1 mutation spectrum 
a
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Allele Mutation 
DNA 
sequenceb 
African 
descended 
European 
descended 
Asian 
descended 
Repercussions Project 
MMalton 
MPalermo 
MNichinan 
Phe52del TTTttcTCC 
   
AATD: protein 
deficiency (12%) + 
intrahepatic 
deposition 
 
 Phe52Ser TTCTCC 
 
0.000 
 
Probably damaging ESP 
Siiyama Ser53Phe TCCTTC    
AATD: protein 
deficiency (7%) + 
intrahepatic 
deposition 
 
M6Passau Ala60Thr GCC ACC  0.001  Probably damaging ESP 
MMineral Gly67Glu GGGGAG    Probably damaging  
Q0Lisbon Thr68Ile ACCATC    
AATD: Protein 
absence 
 
 Asp71Glu GACGAA 
 
0.001 
 
Non-pathogenic 
 
 Thr72Ala ACTGCT 0.000 
  
Possibly damaging ESP 
 Leu84Arg CTCCGC 
 
0.000 
 
Non-pathogenic ESP 
ZBristol Thr85Met ACGATG    
AATD: protein 
deficiency (60%)  
Q0Ludwisghafen Ile92Asn ATCAAC    
AATD: protein 
absence  
M2, M4, T, 
PDuarte 
Arg101His CGTCAT 0.036 0.165 
 
Non-pathogenic 
ESP, 
1000GENOMES, 
HapMap 
Q0Devon 
ZNewport 
Gly115Ser GGCAGC 0.005 0.021 
 
AATD: protein 
deficiency 
ESP 
 Leu120Phe CTCTTC 0.000   Possibly damaging ESP 
Table 6: (Cont.) 
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Allele Mutation 
DNA 
sequenceb 
African 
descended 
European 
descended 
Asian 
descended 
Repercussions Project 
 Lys129Glu AAGGAG 
 
0.000 
 
Probably damaging ESP 
 Ala142Asp GCCGAC 0.000 
  
Probably damaging ESP 
V, MNichinan Gly148Arg GGGAGG  
0.001 
 
Non-pathogenic ESP 
M2Obernburg Gly148Trp GGGTGG  0.001  Probably damaging ESP 
 Glu151Lys GAGAAG 0.000 
  
Non-pathogenic ESP 
Q0Granite Tyr160framStop160 TAcGTG    
AATD: protein 
absence  
 Val161Met GTGATG 0.000 0.000 
 
Probably damaging ESP 
PGaia Glu162Gly GAGGGG    Probably damaging  
 Leu172Ser TTGTCG 
 
0.000 
 
Probably damaging ESP 
 Lys193Stop AAATAA 
   
AATD: protein 
absence  
Q0Trastevere Trp194Stop TGGTGA    
AATD: protein 
absence  
 Pro197His CCCCAC 0.000 
  
Probably damaging ESP 
 Glu204Lys GAGAAG 
   
Non-pathogenic 
 
 Asp207Glu GACGAA 
 
0.000 
 
Non-pathogenic ESP 
 Val210Met GTGATG 0.000 
  
Non-pathogenic ESP 
M1Ala213 Val213Ala GTGGCG 0.459 0.788 
 
Non-pathogenic 
ESP, 
1000GENOMES, 
HapMap 
Table 6: (Cont.) 
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Allele Mutation 
DNA 
sequenceb 
African 
descended 
European 
descended 
Asian 
descended 
Repercussions Project 
 Val216Met GTGATG 0.000 
  
Probably damaging 
ESP, 
1000GENOMES 
Q0Bellingham Lys217Stop AAGTAG    
AATD: protein 
absence  
F Arg223Cys CGTTGT 0.001 0.004 
 
AATD: protein 
deficiency (15%) 
ESP, 
1000GENOMES 
 Cys232Trp TGTTGG 
   
Probably damaging 
 
 Lys233Asn AAGAAT 
 
0.000 
 
Non-pathogenic ESP 
PLowell Asp256Val GATGTT 0.0004 0.001  
AATD: protein 
deficiency (30%) 
ESP 
 Gly258Arg GGGAGG 0.000 
  
Probably damaging ESP 
Q0Cairo Lys259 stop AAATAA    
AATD: Protein 
absence 
 
 His262Tyr CACTAC 0.002 
  
Non-pathogenic ESP 
Q0Gaia Leu263Pro CTGCCG    
AATD: structure 
alteration 
 
S, T Glu264Val GAAGTA 0.010 0.041 
 
AATD: protein 
deficiency (60%) 
ESP, 
1000GENOMES, 
HapMap 
 His269Gln CACCAA 0.002 
  
Non-pathogenic ESP 
 Asn278Ile AATATT 0.000 
  
Non-pathogenic ESP 
Q0Oliveira do 
Douro,  
Arg281framStop297 CAgaAG    
AATD: protein 
absence 
 
 Ala284Ser GCC TCC 
 
0.004 
 
Non-pathogenic 
ESP, 
1000GENOMES 
 Ile293framStop298 GAT^G 
   
AATD:  protein 
absence  
Table 6: (Cont.) 
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Allele Mutation 
DNA 
sequenceb 
African 
descended 
European 
descended 
Asian 
descended 
Repercussions Project 
 Val302Ile GTCATC 0.002 
  
Non-pathogenic 
ESP,    
 1000 GENOMES 
Q0Hong Kong Leu318framStop334 CTC^TC    
AATD: protein 
absence 
 
Q0New Hope Gly320Glu GGG GAG    
AATD: protein 
absence 
 
 Gly320Arg GGGAGG 
 
0.000 
 
Probably damaging ESP 
 Ala325Pro GCACCA 
 
0.000 
 
Non-pathogenic ESP 
 Pro326Ser CCCTCC 0.000 
  
Non-pathogenic ESP 
 Leu327framStop338 CtGAAG 
   
AATD: protein 
absence  
SMunich Ser330Phe TCCTTC  
0.000 
 
Possibly damaging ESP 
 Val333Met GTGATG 0.000 
  
Possibly damaging ESP 
King’s His334Asp CATGAT    
AATD: Delay 
secretion 
 
 Lys335Glu AAGGAG 
  
0.003 Possibly damaging 1000GENOMES 
Wbethesda Ala336Thr GCTACT 
   
AATD: protein 
deficiency (60%)  
 Val337framStop354 GTgCTG 
   
AATD: protein 
absence  
 Ile340Val ATCGTC 
 
0.001 
 
Non-pathogenic 
 
 Asp341Glu GACGAG 
   
Possibly damaging 1000GENOMES 
PDonauworth,  Asp341Asn GACAAC 0.002   Non-pathogenic ESP 
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Allele Mutation 
DNA 
sequenceb 
African 
descended 
European 
descended 
Asian 
descended 
Repercussions Project 
Z Glu342Lys GAGAAG 0.005 0.016 
 
AATD: protein 
deficiency (15%) + 
intrahepatic 
deposition 
ESP, 
1000GENOMES 
 Gly349Trp GGGTGG 
   
Probably damaging HapMap 
Q0Mattawa Leu353framStop376 TTT^T    
AATD: protein 
absence  
MPittsburgh Met358Arg ATGAGG    Altered function  
 Met358Ile ATGATA 0.000 
  
Non-pathogenic ESP 
Loffenbach Pro362Thr CCCACC 
 
0.001 
 
Non-pathogenic ESP 
 Pro362Ser CCCTCC 
   
Non-pathogenic ESP 
Q0Bolton Pro362framStop373 CccGA    
AATD: protein 
absence  
Q0Clayton Pro362framStop376 CCC^C    
AATD: protein 
absence  
XChristchurch Glu363Lys GAGAAG   0.002 Non-pathogenic 1000GENOMES 
MHerleen Pro369Leu CCCCTC 0.000   
AATD: protein 
deficiency (2%) 
ESP 
Mwurzburg Pro369Ser CCCTCC  
0.001 
 
AATD: protein 
deficiency (15%) + 
intrahepatic 
deposition 
ESP, 
 1000 GENOMES 
Q0Vila Real Met374framStop392 TAatgaTT    
AATD: protein 
absence 
 
 Ile375Val ATTGTT 
 
0.000 
 
Non-pathogenic ESP 
M3, M2 Glu376Asp GAAGAC 0.107 0.258 
 
Non-pathogenic 
ESP,  
1000 GENOMES, 
HapMap 
Table 6: (Cont.) 
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 a SERPINA1 mutation data was retrieved from ensemble (http://www.ensembl.org/index.html) and specialized literature 26,81 
 b nucleotide substitution are underlined, deletions are presented as lower case and insertions are preceded by ^ symbol  
 
 
 
 
 
 
 
 
Allele Mutation 
DNA 
sequenceb 
African 
descended 
European 
descended 
Asian 
descended 
Repercussions Project 
 Met385Val ATGGTG 
 
0.000 
 
Non-pathogenic ESP 
 Gln393Leu CAACTA 
 
0.001 
 
Non-pathogenic 
 
Q0Isola di 
Procida 
Del 17Kb inc exons II-
V 
    
AATD: Gene 
deletion 
 
Splice site mutations 
Q0Porto IVS1C+1GA GTAT    
AATD: protein 
absence  
Q0Faro IVS1C+3^insT     
AATD: abolish 
mRNA synthesis 
 
 IVS2+1GT GTTT 
   
AATD: protein 
absence  
 IVS2-1Gdel AgGA 
   
AATD: protein 
absence  
Table 6: (Cont.) 
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Overall, the vast majority of pathogenic mutations are nucleotide substitutions 
61% (24/39) either causing amino acid replacements 71% (17/24), or the insertion of a 
premature termination codon 21% (5/24) or altering the normal of mRNA processing 
8% (2/24). The remaining pathogenic mutations 39% (15/39) are small insertions or 
deletions (indels) leading in most cases to the alteration of reading frame and 
premature termination (Table 6). 
    
Hypermutable Sequences  
In the human genome mutations events are more prone to occur in short 
hypermutable segments, defined by specific DNA sequences such as mononucleotide 
repeats stretches or CpG dinucleotides82,83. 
Repeated sequences are recognized as an important factor for mutagenesis 
due to misalignments during the DNA replication. In the coding region of SERPINA1 we 
identified 7 stretches of 5 or more mononucleotide repeats, however only two could be 
associated to insertions and deletions.  The thymine stretch (T)5 located in 352 and 
353 codons is implicated in two independent mutational events of Leu353framStop376 
frameshift (Q0Ourém and Q0Mattawa) and the cytosine (C)7 located in codons 360 to 362 is 
enrolled two different frameshift mutations: Pro362framStop376 and 
Pro362framStop373  
 The Phe52del occur in a region that might be considered a repeat stretch as 
well, the codons 50 to 53 contain a TCT motif repeated 3 times (ATC-TTC-TTC-TCC) 
that could have facilitated the loss of an entire codon 52 in MMalton and MPalermo alleles
32.  
CpGs are the most hypermutable motifs associated to single nucleotide 
polymorphisms (SNPs) and mutations in CpGs occurs 10 times more frequently than in 
any other dinucleotide. This hypermutability is associated to cytosine methylation that 
once deaminated leads to a nucleotide change to thymine, resulting in CGTG or 
CGCA substitution depending on the strand the methylated cytosine82,83.          
 In the coding region of SERPINA1 we identified a total of 29 CpGs. Among 
these 19 (65.5%) were target of at least one mutation event and 11 (57.9%) causing 
pathogenic or damaging mutations.  
   The remaining single mutations 73 (79.3 %) could not be correlated to any 
hypermutable motif and probably result from other genomic mechanism of DNA 
sequence mutability. 
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  Overall, this analysis shows that in most cases SERPINA1 mutations are 
determined by other mechanisms of mutagenesis rather than CpG or mononucleotide 
stretches, like it was observed in loci and genomic regions. However, short repeat 
motifs seem to play an important role in indels which are associated, in most cases, to 
pathogenic mutation, while CpG are evenly distributed between pathogenic, damaging 
and non-pathogenic mutations. 
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4.1.3 Conservation and functional implications  
Residue conservation across ortholog and paralogs is often used as a predictor 
for the effect of non-synonymous mutations and frequently implemented in 
bioinformatics tools such as Polyphen and SIFT. On the other hand, the analysis of the 
distribution of pathogenic mutations allows the identification of critical regions in the 
molecule affecting protein structure and stability. In addition, extensive surveys of the 
different categories of mutations (pathogenic, damaging and non-pathogenic) across 
coding regions of specific genes may facilitate the identification of unknown 
hypermutable sequences.   
In Figure 21, we show pattern of SERPINA1 evolution across 18 vertebrates as 
inferred by maximum likelihood phylogenetic analysis (site model M3). In the time scale 
of vertebrates divergence (approximately 400 million years)84 SERPINA1 sites 
experienced different levels of purifying selection. About 25% of SERPINA1 residues 
remained almost unchanged throughout the phylogeny (ω0=0.031, p0=0.254), 54% 
were still strongly conserved (ω1=0.269, p1=0.541) and 21% evolved under less 
constraints or as nearly neutral residues (ω2=1.120, p2=0.205). The overlap of the 
SERPINA1 mutational spectrum with its evolutionary pattern shows that all pathogenic 
mutations are placed in strongly conserved residues (ω0 or ω1). Interestingly, 
pathogenic mutations are not evenly distributed by highly conserved residues. In 
contrary, pathogenic mutations aggregate in three major clusters (38-115; 193-264 and 
320-369). In the first cluster, we detected two critical regions in SERPINA1 structure 
associated to pathogenic mutations A α-helix (38-41 residues) and 6B β-strand (52-53 
residues: shutter domain). In the second cluster, we identified a larger affected 
structural region from 3B β-strand to G α-helix (256-264 residues) in an important 
functional domain of the molecule, the gate. In the third cluster, another crucial region 
lies between 334 and 342 residues which correspond to 5A β-strand and overlaps with 
SERPINA1 shutter domain. 
In contrary, non-pathogenic mutations appear to be uniformly distributed by 
SERPINA1 and among these 55% (17/32) were located still in conserved residues (ω0 
or ω1). The mutations classified as damaging by bioinformatic tools are located in 
conserved residues with the exception of two cases (-18 and 148). As mentioned 
above, we are aware of the importance of the biochemical properties of each residue in 
the level pathogenicity of the different mutations. However, from the distribution of 
pathogenic mutations we would guess that only the mutations located in the pathogenic 
clusters are likely to include some truly damaging variants.  
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Finally, taking together the mutation spectrum of SERPINA1 and its evenly 
distribution across the coding region there is no clear region that stands out for an 
higher mutability besides CpGs, 52 and 53 codons and mononucleotide repeats 
stretches.  
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Figure 21:  Graphic distribution of SERPINA1 residue conservation based on alignments of 18 vertebrates species and mutational spectrum.  Posterior probability for three different sites classes obtained 
by maximum likelihood using a phylogenetic tree built with 18 SERPINA1 ortholog sequences. Amino acids are numbered according to human SERPINA1 sequence. The mutations are described in Table 6 and are 
represented by , ,  corresponding to pathogenic, damaging and non-pathogenic mutations, respectively. Mutations leading to changes of the reading frame and to the introduction of premature termination 
codons were not included in this analysis.  
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4.2 SERPINA2 
  4.2.1 SERPINA2 genotyping in GPA cases and 
controls 
 A sequencing study of the coding region of SERPINA2 was done in 54 ZZ 
individuals, 44 controls from Portugal and Birmingham (England) diagnosed with 
COPD or emphysema and 10 GPA cases from Birmingham (England) and Bochum 
(Germany).   
 In our control sample from Portugal, all ZZ were found to be linked to the 
previously described V3 (Pro308-Glu320)54 variant of SERPINA2, except for a 
heterozygous V3/V2 (Leu308-Glu320) (Table 7). This individual was found to carry a 
chromosome with the Z mutation in a M1Val background instead of M1Ala, suggesting 
a possible occurrence of Glu342Lys (Z allele) mutation in an extended haplotype 
comprising a M1Val and a SERPINA2 V2 variant.  
   
          Table 7: SERPINA2 haplotypes identified in ZZ controls from Portugal and Birmingham. 
Ancestral Haplotype C C T G 
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chromosomes 
Portugal 
C C C G 47(V3) 
C C T G 1(V2) 
Birmingham 
C C C G 39(V3) 
T - C G 1 
   
 
 
  Apart from this SERPINA2 variant, only two other SNPs were identified among 
ZZ individuals. This included a synonymous substitution Thr58(ACC)Thr58(ACT) and 
a C deletion causing a premature stop codon (Leu108framStop117) identified in a 
single subject from Birmingham (Table 7). Both mutations have been previously 
described and found to be in complete linkage disequilibrium53. Except for two 
compounds heterozygous (1 Portuguese and 1 English) the SERPINA2 haplotypes in 
ZZ controls are quite homogeneous within and between populations and associated to 
the V3 variant (~95%). 
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Table 8: SERPINA2 haplotypes identified in GPA samples from Birmingham and Bochum. 
Ancestral 
Haplotype  
G C T C T G G 
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Number of 
chromosomes 
Birmingham 
G C T C C G G 8(V3) 
G T T - C G G 1 
G C T C C A G 1 
Bochum 
G C T C C G G 7 (V3) 
A C T C T G G 1(V2) 
G C G C T G G 1 
G C T C C G A 1(V1) 
 
  
Conversely, the samples from GPA patients showed a higher level of sequence 
variation than ZZ control samples, even considering its reduced sample size. We 
identified three additional SNPs: two associated with synonymous substitutions in 
codon positions 24 (Glu24Glu) and 77 (Thr77Thr) and another one causing a non-
synonymous replacement in 312 codon (Gly312Asp) not described before. According 
to bioinformatics predictions this novel variant is likely to have serious repercussions in 
SERPINA2 structure (Polyphen-2 score 1.00- probably damaging; 
http://genetics.bwh.harvard.edu/pph2/). 
 Overall, in the two GPA samples we detected a loss of function haplotype 
containing the synonymous Thr58 and C deletion alleles and four other haplotypes not 
observed in ZZ controls including a V1 (Pro308-Lys320) haplotype, two V2-like 
haplotypes carrying different synonymous mutations and V3-like haplotype 
encompassing the novel Gly312Asp variant (Table 8). These haplotypes were found in 
heterozygosity with V3 haplotypes indicating that only 3 GPA patients in Birmingham 
(60%) and 2 patients in Bochum (40%) are homozygous for V3 variant, which is the 
main genotype found among non-GPA ZZ subjects.  
   Even though preliminary, our results may suggest that a considerable fraction 
of GPA patients lost the common V3 haplotype by recombination with other SERPINA2 
haplotypes, further advancing the hypothesis of a GPA protective role of the V3 
(Pro308-Glu320) variant of SERPINA2. To substantiate this suggestion it is necessary 
to enlarge both control and GPA samples to verify if the same level of differentiation 
between samples is maintained. Furthermore, the inclusion of additional controls from 
Germany could help discarding the hypothesis of the observed differences being 
related to geographic differences. Taking into account the relative young age of the Z 
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allele replicated in different populations and the low local recombination rates we 
expect control samples to include a relative small number of recombinant Z 
chromosomes.  
 
4.2.2 Expression of SERPINA2 
 We PCR amplified SERPINA2 (V2) cDNA sequence from SERPINA2/pLenti6V5 
plasmid54 and generated two novel constructs SERPINA2/pIEX5 (Novagen) and 
SERPINA2/pTT5 (collaboration partner),  both containing a stable His-tag. These were 
later used to transient transfected two different host cell lines. The SERPINA2/pIEX5 
vector was used to transfect Drosophila Schneider S2 cells, and the SERPINA2/pTT5 
vector was used to transfect human HEK293 cells. In both cell system, ninety six hours 
after transfection recombinant SERPINA2 was collected from cultured cell 
supernatants. The purification of supernatants from Schneider S2 was performed by 
overnight dialysis in EB buffer containing 10mM, imidazole and then with the protocol 
of a Äkta Prime Plus system by collecting 13 elution fractions. Afterwards the fractions 
of interest were concentrated by ultra-centrifugation. In case of HEK293, supernatants 
were concentrated by a single ultra-centrifugation step and purified by use of nickel a 
column. The purified protein was later analysed by western blot with an antibody 
against the His-tag and a specific antibody against SERPINA2 (Figure 22). 
 
 
 
 
            
     
Figure 22: Expression of SERPINA2.  A – Western blot of supernatants from Drosophila Schneider S2 transfected with 
a SERPINA2/pIEX5 vector. SERPINA2 was detected using anti-His-tag 3D5 (a) and anti-SERPINA2 (G12) (b); B- 
Western blot of supernatants from HEK 293 cells transfected with SERPINA2/pTT5 construct. SERPINA2 was detected 
using anti-His-tag 3D5. MW – molecular weight ladder. F4, F5, F6, F7 and F8 correspond to SERPINA2 fractions 
obtained from the supernatant after purification. 
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 Our results confirmed SERPINA2 expression in both cellular systems used, 
however, a stronger signal was obtained in S2 cells, particularly in the purified protein 
fraction 5 (Figure 22A). Such marked difference between the two systems results from 
a more efficient protein secretion in Drosophila S2 cells comparing to human HEK293 
cells where most of the protein was retained intracellularly. This result is consistent with 
previous reports of the SERPINA2 recombinant protein expression in mammalian cell 
lines HeLa and CHO54.  
  The Drosophila Schneider S2 cells  seems to be the best system at present to 
express SERPINA2, however it is necessary to do more expression assays, with 
different constructs. Another central issue of this work is the poor quality of commercial 
antibodies against SERPINA2, which displayed low specificity and low yield when 
compared with the His-tag antibody. Therefore to proceed further in SERPINA2 
expression studies it is important to develop a monoclonal antibody for the protein.    
Previous studies have demonstrated that SERPINA2 is expressed in 
leukocytes, testis and other tissues53,54 and when translated the protein is mostly 
retained intracellularly in the ER, nevertheless the inhibitory properties of SERPINA2 
and its function in vivo remains unknown. Therefore, to address whether SERPINA2 
plays a role in GPA either through an independent mechanism of AATD or through an 
combined effect with AATD it is extremely important to disclose the association of 
SERPINA2 variants with Z alleles and to pursue the functional characterization of 
SERPINA2 in vitro and in vivo. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.Conclusions 
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In our Portuguese cohort of 51 cases with AATD caused by rare variants of 
SERPINA1, we identified a total of 13 mutations and 14 alleles. Among these 5 were 
novel and described for the first time in the current work: Q0Gaia (Leu263Pro), PGaia 
(Glu162Gly), Q0OilveiradoDouro (Arg281framStop297), Q0Vila Real (Met374framStop392) and 
Q0Faro (IVSIC+3Tins).  
The amino acid substitutions Leu263Pro and Glu162Gly occur both in two 
highly conserved residues among SERPINA1 orthologs. However, the Leu263Pro 
mutation like other replacements in which leucine and proline residues are enrolled, 
has more serious effects in protein structure (protein absence) than the Glu162Gly 
substitution (protein deficiency). 
 The two frameshift mutations Arg281framStop297 and Met374framStop392 
both result from small deletions leading to premature stop codons in SERPINA1 exons 
IV and V, respectively. Whereas the Arg281framStop297 mutation is expected to be 
associated to the lack of transcripts due to their degradation by NMD processes, the 
Met374framStop392 is expected to be linked to an unstable protein and normal 
transcripts levels because of its close proximity to the canonical SERPINA1 termination 
codon. 
The mutation IVSIC+3Tins disrupts a donor splice site located in the 5’UTR and 
it is predicted to abolish SERPINA1 expression in hepatocytes but not in mononuclear 
phagocytes. There, the presence of upstream translation initiation sites and the 
occurrence of alternative splicing warrant SERPINA1 expression. To our knowledge, 
this is the fourth example of splice site mutation in SERPINA1 and the second case of 
a mutation in the 5’UTR associated to severe AATD. 
The alleles previously described elsewhere in Europe and detected in our 
cohort AATD cases included: MMalton, MPalermo (Pher52del was found to be the most 
prevalent rare mutation in Portugal), I, PLowell, MHerleen and Mwurzburg. The remaining rare 
alleles Q0Ourém and Q0Lisbon seem to be restricted to the Iberian Peninsula.   
 The haplotype characterization of MMalton and MPalermo alleles uncovered the 
independent origin of the Phe52del mutation in M2 and M1 molecular background, 
respectively, in contrary to I, PLowell and Q0Ourém alleles, which appear to have had all a 
single origin. The analysis of intrahaplotipic diversity also showed that the alleles 
present in different European populations (MPalermo, I and PLowell) tend to display higher 
variability than alleles confined to a smaller geographic region (Q0Ourém). This finding 
suggests a more ancient origin of dispersed alleles than the Q0Ourém allele, which was 
estimated to have arisen in the middle ages. 
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In this work, we also used SERPINA1 haplotypes to elucidate the origins of the 
T allele, which in our case it is likely to result from a recombination event between S 
(Glu264Val) and M2 or M3 (Glu376Asp) chromosomes. 
The in-depth analysis of the SERPINA1 mutational spectrum showed that one 
fourth of the mutations are not randomly distributed and tend to occur in hypermutable 
motifs. The small deletions leading to Leu353framStop376, Pro362framStop376 and 
Pro362framStop373 mutations all occur in mononucleotide repeat motifs and the 
Phe52del mutation occurs in a short trinucleotide repeat sequence. All these mutations 
might have arisen by a misalignment during DNA replication. CpGs are another 
hypermutable motif because cytosines once methylated are prone to deamination and 
modification into a thymine nucleotide. In the SERPINA1 coding sequence more than a 
half of CpG dinucleotides were found to be mutated. 
 The study of the non-synonymous mutations distribution across SERPINA1 
disclosed a clustering of pathogenic mutations in two functional domains of the protein 
structure: the shutter (6B β-stand and 5A β-stand) and the gate (3B β-stand to G α-
helix). In contrary, the non-pathogenic mutations were found to be evenly spread in 
SERPINA1. The analysis of SERPINA1 residue conservation confirmed that all 
pathogenic mutations are placed in highly conserved residues, but the location of a 
mutation in a conserved residue does not necessary corresponds to pathogenic 
mutation given that 55% of non-pathogenic mutations are still located at conserved 
residues.  
 The sequencing survey of SERPINA2 in 44 controls and 10 GPA cases, 
revealed a large homogeneity between Z chromosomes in both Portuguese and 
Birmingham samples, which were in most cases associated to SERPINA2V3 variant. 
On the other hand, among GPA cases a considerable lower number of Z chromosomes 
were associated to the SERPINA2V3 variant. This finding suggests a potential 
contribution of the loss of SERPINA2/V3 variant into a higher risk of GPA.  
The Drosophila Schneider S2 cells are so far the best system for SERPINA2 
expression since in HEK293 and other mammalian cell lines the protein tend to 
accumulate intracellularly in the endoplasmic reticulum.                
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SERPINA1 
F1 F2 F3 
Long PCR primers  
(5’ to 3’)  
Sequencing primers 
 (5’ to 3’)   
Long PCR primers  
(5’ to 3’)  
Sequencing primers 
 (5’ to 3’)  
Long PCR primers  
(5’ to 3’)  
Sequencing primers 
 (5’ to 3’)  
Primers 
˗AACCAGTGTATCCACCAG
GA 
˗CAGAAACCTGCCAGTTAT
TG 
Primers 
˗TCCTGTGCCTGCCAGAA
GAG 
˗CATTGTGCAGATGGGAAA
AC 
˗TCCTCACAGCAGCTCAAC
AA 
˗GTGGAACAGCCACTAAG
GAT 
˗ATCAGGCATTTTGGGGTG
ACT 
Primers 
˗TCCCTGATCACTGGGAGT
CAT 
˗AGGAAGCCCATCTGTTCC
TT 
Primers 
˗TCATCATGTGCCTTGACT
CG 
˗TTCAGCCTATACCGCCAG
CT 
˗CAATGCATTATGGGCCAT
AG 
˗ATGACAAAGACTGTGGG
GAT 
˗AAGTTCTGCAGAGCGTCA
GTA 
˗GCTGAAACTGACCATCCA
AG 
˗CCACCTTCCCCTCTC 
Primers 
˗TTCCAAACCTTCACTCAC
CCCTGGTGATG 
˗GAGGAGCGAGAGGCAGT
TATT 
Primers 
˗GGGCCTCAGTCCCAACA
TGGCTAAGAGG 
˗GCCTTGAATTTCTTT 
˗CACTGAGTTCAGGCAGC
GGC 
˗ACACATTCTTCCCTACA
GATACCATGGTGC 
˗ATCAGCCTTACAACG 
˗GATTGAACAAAATACCA
AGTCTC 
Table A 1: PCR primer list and conditions for SERPINA1 amplification and sequencing. 
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SERPINA1 
F1 F2 F3 
Long PCR  
conditions 
Sequencing  
conditions 
Long PCR  
conditions 
Sequencing  
conditions 
Long PCR  
conditions 
Sequencing  
conditions 
Conditions  
 
94ºC 2 min (1 cycle)94ºC 
10s, 56ºC 30s, 68ºC 2 min 
30s (10 cycles)94ºC 10s, 
54ºC 30s, 68ºC 2 min 30s 
plus 3s per cycle (30 
cycles)68ºC 20 min 
 
Conditions 
 
96ºC 10 sec, 65ºC 1min (6 
cycles) 
96ºC 10 sec, 64ºC 1min (6 
cycles) 
96ºC 10 sec, 63ºC 1min (6 
cycles) 
96ºC 10 sec, 62ºC 1min (6 
cycles) 
96ºC 10 sec, 61ºC 1min (6 
cycles) 
96ºC 10 sec, 60ºC 1min (6 
cycles) 
96ºC 10 sec, 59ºC 1min (6 
cycles) 
96ºC 10 sec, 58ºC 1min (6 
cycles) 
96ºC 10 sec, 57ºC 1min (6 
cycles) 
96ºC 10 sec, 56ºC 1min (6 
cycles) 
96ºC 10 sec, 55ºC 1min (6 
cycles) 
Conditions 
 
94ºC 2 min (1 cycle) 
94ºC 10s, 56ºC 30s, 68ºC 2 
min 30s (10 cycles) 
94ºC 10s, 54ºC 30s, 68ºC 2 
min 30s plus 3s per cycle 
(30 cycles) 
68ºC 20 min 
Conditions 
 
96ºC 10 sec, 65ºC 1min (6 
cycles) 
96ºC 10 sec, 64ºC 1min (6 
cycles) 
96ºC 10 sec, 63ºC 1min (6 
cycles) 
96ºC 10 sec, 62ºC 1min (6 
cycles) 
96ºC 10 sec, 61ºC 1min (6 
cycles) 
96ºC 10 sec, 60ºC 1min (6 
cycles) 
96ºC 10 sec, 59ºC 1min (6 
cycles) 
96ºC 10 sec, 58ºC 1min (6 
cycles) 
96ºC 10 sec, 57ºC 1min (6 
cycles) 
96ºC 10 sec, 56ºC 1min (6 
cycles) 
96ºC 10 sec, 55ºC 1min (6 
cycles) 
Conditions 
 
94ºC 2 min (1 cycle)94ºC 
10s, 58ºC 30s, 68ºC 2 min 
30s (10 cycles)94ºC 10s, 
56ºC 30s, 68ºC 2 min 30s 
plus 3s per cycle (30 
cycles)68ºC 20 min 
 
Conditions 
 
96ºC 10 sec, 65ºC 1min 
(6 cycles) 
96ºC 10 sec, 64ºC 1min 
(6 cycles) 
96ºC 10 sec, 63ºC 1min 
(6 cycles) 
96ºC 10 sec, 62ºC 1min 
(6 cycles) 
96ºC 10 sec, 61ºC 1min 
(6 cycles) 
96ºC 10 sec, 60ºC 1min 
(6 cycles) 
96ºC 10 sec, 59ºC 1min 
(6 cycles) 
96ºC 10 sec, 58ºC 1min 
(6 cycles) 
96ºC 10 sec, 57ºC 1min 
(6 cycles) 
96ºC 10 sec, 56ºC 1min 
(6 cycles) 
96ºC 10 sec, 55ºC 1min 
(6 cycles) 
Table A 1: (Cont.) 
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Table A 2: PCR primer list and Conditions for SERPINA2 amplification and sequencing.   
SERPINA2 
F1 F2 F3 
Long PCR primers 
(5’ to 3’) and conditions  
Sequencing primers 
(5’ to 3’) 
Long PCR primers 
(5’ to 3’)  and conditions 
Sequencing primers 
(5’ to 3’) 
Long PCR primers 
(5’ to 3’)  and conditions 
Sequencing primers 
(5’ to 3’) 
Primers 
˗TGGTTGCAATCACACAAT
GTCA 
˗AACGGGCTTGGACAGGT
AG 
 
Primers 
˗GGAAAGGCCTCAGGAGA
AGT 
 
 
Primers 
˗GGAAAGGCCTCAGGAGA
AGT 
˗AGCCCCTGAACTGGAAAT
CA 
 
Primers 
˗GGAAAGGCCTCAGGAGA
AGT 
 
 
Primers 
˗AGTGGGAGACGCAATCA
GAA 
˗AGTGCACAAAGGGAGAG
TCA 
 
Primers 
˗CCTTCTTCAGCCTCA
GGACA 
˗ACCTCCTAGGATGAG
GCTGT 
 
Conditions 
 
95ºC 15 min (1 cycle)94ºC 
10s, 60ºC 30s, 72ºC 1 min (3 
cycles)94ºC 10s, 58ºC 30s, 
72ºC 1 min (3 cycles)94ºC 
10s, 56ºC 30s, 72ºC 1 min 
(29 cycles)72ºC 10 min 
 
 Conditions 
 
95ºC 15 min (1 cycle)94ºC 
10s, 60ºC 30s, 72ºC 1 min (3 
cycles)94ºC 10s, 58ºC 30s, 
72ºC 1 min (3 cycles)94ºC 
10s, 56ºC 30s, 72ºC 1 min 
(29 cycles)72ºC 10 min 
 
 Conditions 
 
95ºC 15 min (1 cycle)94ºC 
10s, 60ºC 30s, 72ºC 2 min (3 
cycles) 
94ºC 10s, 58ºC 30s, 72ºC 2 
min (3 cycles) 
94ºC 10s, 56ºC 30s, 72ºC 2 
min (29 cycles) 
72ºC 10 min 
 
 
